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Abstract

The ventromedial hypothalamic nucleus (VMH) plays an important role in the
regulation of food intake, glucose metabolism, and body weight. However, in contrast to
other hypothalamic nuclei that are also known to regulate energy homeostasis, there is a
paucity of nucleus-specific marker genes for the VMH that can be used to label its
constituent neurons.

This represents a significant impediment to the application of

molecular approaches for analyzing VMH circuitry and function.
Thus, we conducted a microarray screen in order to identify VMH-specific genes
that could be used to label populations of VMH neurons. Laser-capture microdissection
was used to isolate RNA from the VMH and from two adjacent hypothalamic nuclei
known to play a role in energy balance, the arcuate (ARC) and dorsomedial hypothalamic
nucleus (DMH). Amplified RNA from these three nuclei were intercompared to identify
genes with VMH-enriched expression. The top 12 VMH marker gene candidates were
screened by real-time PCR, and three genes (Cerebellin 1, PACAP, and a novel gene we
characterized, LBH2) were examined by in situ hybridization for further validation and
examination of their subnuclear expression profile.
One of the VMH markers, steroidogenic factor 1 (SF-1), is an orphan nuclear
receptor with few known target genes. As this transcription factor is responsible for
proper developmental formation of the VMH and also for normal energy homeostasis, we
endeavored to determine whether any of the VMH marker genes may be regulated by SF1. The expression of 4 markers was significantly altered in VMH neurons of SF-1
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knockout mice, and this result was confirmed by an in situ hybridization study of
cerebellin 1 expression in brain-specific SF-1 knockout mice.
One of the VMH markers was a previous undescribed gene that we further
characterized and named LBH2 owing to its similarity to a presumed transcription factor
called limb bud and heart (LBH). To further examine the expression of this gene in the
VMH, and to begin to describe VMH neuronal populations, we created LBH2-GFP BAC
transgenic mouse line expressing GFP under the control of the LBH2 promoter. These
mice were validated for correct expression of the transgene and examined for overlap
with other populations of interest in the VMH, including estrogen receptor-alpha neurons
and leptin-responsive neurons.
Finally, we used a TK+ strain of PRV Bartha2001 to trace neuronal inputs from
AgRP neurons in the ARC using AgRP-cre mice. Using this technique, it could be
determined that the dorsomedial and intermediate VMH sends significant outputs to this
population of ARC neurons. This technique, together with the marker genes discovered,
may now be used to identify and catalog individual VMH neuronal subsets that project to
these neurons.
In conclusion, we have discovered a set of marker genes for the VMH using lasercapture microdissection coupled with cDNA microarray analysis. This combination of
techniques represents a powerful approach for the identification of genes enriched in
specific, anatomically-defined brain regions. The discovery of multiple genes regulated
by SF-1 also suggests this technique may be useful for identifying nucleus-specific
transcriptional networks. The VMH-enriched genes identified here, in conjunction with
LBH2-GFP mice and other transgenic animals, will provide a basis for a full
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characterization of VMH neurons, and will prove greatly useful for future neuroanatomic
and transgenic-based studies of this important nucleus.
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Chapter 1: Introduction

Obesity
Obesity is fast becoming an urgent worldwide health problem. No longer just
restricted to the United States and the rest of the developed world, obesity is now
commonplace among the world’s developing countries, often co-existing side-by-side
with undernutrition (WHO, 1997; Caballero, 2001).The scope and pace of the global
obesity epidemic, as well as its serious health and financial consequences, highlight the
demand for rapid, effective research and action.
According to the most recent study by the National Center for Health Statistics
(1999-2002), 30% of adults in the United States are obese, with an additional 35%
overweight (Flegal et al., 2002). This represents a substantial increase over the previous
survey conducted between 1988-1994, when 23% and 33% of adults were found to be
obese and overweight, respectively (Kuczmarski et al., 1994). While the United States is
the most overweight large industrialized country, the US numbers are being mirrored by
developed countries worldwide (Saitoh et al., 1999; Seidell, 2002). Recently, developing
countries have begun to be affected as well, and in many the incidence of overweight and
obesity is higher than that of undernutrition (Monteiro et al., 2004). For example, the
incidence of overweight exceeds 30% in Peru, Tunisia, Brazil, Colombia, and Costa Rica,
according to a 1997 World Health Organization survey (WHO, 1997). Additionally,
more than 60% of the population of urban Samoa fits the definition of obesity (Hodge et
al., 1994). In total, it is estimated that there were 300 million obese people worldwide in
the year 2000, and this number continues to rise (WHO, 2000).
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Perhaps most disturbing of all are the statistics regarding young people.
According to the NHANES study, 16% of US youths 6-19 were found to be overweight,
a sharp increase from 11% in 1994 and 6% in 1980 (Ogden et al., 2002; Hedley et al.,
2004). This is of particular concern, as childhood adiposity is a strong predictor for adult
adiposity and its concomitant risks (Steinberger et al., 2001). These trends are now being
observed worldwide (Dehghan et al., 2005).
Obesity is a complex disease with a multitude of deleterious consequences.
Obese individuals are significantly at risk for a number of series diseases and afflictions,
including but not limited to type 2 diabetes mellitus, hypertension, coronary heart
disease, cancer, osteoarthritis, cholelithiasis, and sleep apnea (Fig. 1) (Kopelman, 1994,
2000). Additionally, overweight and obese individuals may suffer from arthritis, aches
and pains, sleep disturbance, dyspnea, and social stigmatization, all potentially leading to
depression and poor quality of life (Myers and Rosen, 1999; Lawrence and Kopelman,
2004). There are a number of different ways to quantify weight status and obesity.
However, the most commonly used is the body mass index (BMI) scale, whereby BMI
equals the weight in kilograms divided by the square of the height in meters. BMI of
18.5 – 24.9 is considered normal, whereas a BMI of 25.0 – 29.9 is considered overweight
and BMI of 30 or more is considered obese (WHO, 1995; Willett et al., 1999). In the
Framingham Heart study of ~115,000 women, obesity (BMI>30) was specifically linked
to overall mortality and mortality from cardiovascular disease (Hubert et al., 1983). In a
separate study of men, weight elevated 20% above normal was shown to be associated
with elevated mortality (Garrison et al., 1983). Mortality alone does not adequately
represent the full scale of the problem, because a number of the sequelae experienced by
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a

b

Figure 1 Health Risks Associated with Overweight and Obesity
Relationships between BMI and relative risk of type 2 diabetes,
cholelithiasis, hypertension, and coronary heart disease. (a) Women,
age 30 to 55, followed for 18 years. (b) Men, initially 40 to 65 years
old, followed for 10 years. Adapted from Willett et al. 1999.

obese patients are held at bay by expensive medical treatments. Recently, the costs
attributable to obesity were estimated to have eclipsed 78.5 billion dollars annually,
representing 9.1% of all US medical expenditures (Finkelstein et al., 2003).
The historical perspective on obesity is that it is the result of laziness and a lack of
willpower.

This notion is one of the main sources of the stigma experienced by

overweight people (Myers and Rosen, 1999). However, the bulk of the evidence does not
support this theory, instead pointing unmistakably to the conclusion that human body
weight is under strict genetic control (Friedman, 2000). It has long been observed that
obesity tends to cluster within families, but such findings are open to criticism along the
age-old lines of genes vs. environment. Studies of twins have yielded much stronger,
irrefutable data. In one study, the concordance rates for height, weight, and BMI were
found to be twice as high in monozygotic twin pairs as in dizygotic twins, highlighting
the importance of identical vs. similar genetic material within the same environmental
context (Stunkard et al., 1986). Additionally, a study of twins separated at birth and
raised apart found that BMI was correlated with a coefficient of 0.70 for men and 0.66 for
women (Stunkard et al., 1990). This is a higher level of correlation than that observed for
other conditions, such as schizophrenia, commonly regarded as being under genetic
control (Allison et al., 1996). Additionally, because the twin pairs showed such highly
correlated weights despite growing up in different environments, these results suggest
that environment may not be the most important determinant of body weight.
This evidence, taken together, is the basis for what is termed the “set point”
theory of body weight, whereby each person has a particular set-point weight that is
strictly adhered to by the body without, and often despite, conscious control (Schwartz
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and Seeley, 1997). This idea is reinforced by the failure of diet schemes to effect
significant weight loss over long periods of time. All schemes tested to date have
resulted in compensatory weight gain following an initial period of weight loss (Wadden,
1993).
So, if body weight is under strict genetic control, why the recent surge in the
incidence of obesity? Clearly, population genetics cannot vary on such a short time scale
as one or two generations, and there must be some input from the environment.
Humans living in the developed post-industrial world find themselves in a
situation for which their evolutionary history has left them wholly unprepared. Since the
dawn of evolution, organisms have struggled with the pressure to reproduce, evade
predators, and consume and store adequate nutrients. Those organisms that could best
complete these tasks went on to dominate over their weaker competitors. However,
modern affluent humans have largely escaped from each of these selective pressures. In
particular, ever-improving food production and storage technology have made food
readily available to nearly all of our citizens, regardless of economic status.
However, this dramatic success has had far-reaching consequences for our
culture. For example, an entire scientific, economically-driven industry has emerged
whose sole purpose is to best cater to the taste-buds and sensibilities of consumers. Food
manufacturers and restaurants compete with each other to create the best food and flavor
combinations, and the successful competitors survive and grow while the rest perish.
Today, it is the food that competes for the mouths, rather than the other way around. The
result of this is a steady increase in the proportion of fat in the western diet, a factor
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strongly linked with weight gain in multiple studies (Sonne-Holm and Sorensen, 1977;
Curb and Marcus, 1991; Bray and Popkin, 1998).
Taken together, it may be hypothesized that genetic factors set a strict body
weight within a particular environmental context. Stated another way, genetic make-up
determines whether an individual will succumb to obesity within a certain environment.
Clearly, if an individual were to grow up in an environment where food was not plentiful,
obesity would not be a likely outcome regardless of genetics. But, if a thin person were
to move to a country with different food options, availability and culture, the
susceptibility might reveal itself. This hypothesis is born out by studies of immigrants.
In one 2004 study, immigrants to the United States were found to have a far lower rate of
obesity than US-born individuals (8% vs. 22%, respectively) (Goel et al., 2004).
However, among immigrants who had lived in the United States for more than 15 years,
the rate of obesity rose to 19% (Goel et al., 2004). Another study showed that second and
third-generation Asian-American and Hispanic children born in the US were more than
twice as likely to be obese as first generation residents (Popkin and Udry, 1998).
Interestingly, people descended from predominantly hunter-gatherer cultures seem to be
much more susceptible to developing obesity when introduced to a high-fat western diet
than people of agricultural European descent (Friedman, 2003). For example, more than
60% of the Pima Native American tribe living in the Gila River valley of Arizona are
clinically obese, with BMI > 30 (Knowler et al., 1991). Many Pacific island nations,
such as Samoa, have also been severely affected as a result of the introduction of Western
diet following WWII. The common explanation for this phenomenon is that huntergatherers were evolutionarily forced to place a higher premium on energy storage,
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because they faced more routine periods of food deprivation (Neel et al., 1998; Neel,
1999).
Most people would assume that their food intake is voluntarily controlled, and
that they decide when they eat, what they eat, and how much. But, people’s weights do
not fluctuate over the long term, except to perhaps slowly drift upwards, indicating
precise control of caloric intake to within 99.5% (Friedman, 2003). This would tend to
deny the possibility of long-term conscious control of food intake, and necessitate that
each person’s body performs a constant accounting of energy stores and requirements,
dictating exactly how much is eaten over the long-term. If that is the case, how does this
system work?

Hypothalamic Control of Food Intake
Researchers have long been interested in feeding motivation. Originally, it was
not known whether the sensation of hunger was a peripheral or central phenomenon. The
first evidence for CNS control of food intake came from the observation that a significant
proportion of patients with pituitary tumors displayed uncharacteristic hyperphagia and
obesity (Frohlich, 1901). But, while these studies demonstrated that the brain played a
major role in forming and responding to hunger, it was unclear whether damage to the
pituitary itself, or to the overlying hypothalamus, was responsible for the hyperphagia.
Conclusive evidence for hypothalamic regulation of food intake and body weight
came decades later, in the form of classic lesioning studies first performed on rats by
Hetherington and Ranson (Hetherington and Ranson, 1940). Electrolytic lesions to the
ventromedial hypothalamic nucleus (VMH) produced hyperphagia and massive obesity
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(Fig. 2), while lesions to the lateral hypothalamic area (LH) produced aphagia and weight
loss (Hetherington and Ranson, 1940; Anand and Brobeck, 1951). These studies formed
the basis for the dual-center model, whereby the VMH acts as the satiety center and the
LH acts as the feeding center. According to this model, the interplay between the two
regions would then be responsible for determining minute to minute feeding decisions
(Elmquist et al., 1999).
Today, the hypothalamus is recognized as the great homeostatic regulator of the
body (Kandel and Schwartz, 1991). The hypothalamus receives information related to
nearly all homeostatically regulated parameters, such as salt and water levels, blood
pressure, blood glucose, hormone concentrations, and nutrients, and makes compensatory
changes designed to keep them within desirable limits. At the microscopic scale, the
hypothalamus is composed of a number of discrete, densely-packed populations of
neurons called nuclei, which are developmentally regulated to have consistent size,
shape, composition, localization and gene-expression.

The hypothalamus exerts its

homeostatic influence either by signaling via axons to distal brain sites, including
autonomic nervous system centers, and by directing hormone release from the pituitary,
to which it is physically connected via the infundibulum.

The VMH
Although the lesioning experiments did conclusively demonstrate a central role
for the hypothalamus in energy homeostasis, the dual-center model was much criticized.
Many argued that the lesions produced by Hetherington and Ranson were large enough to
damage a number of other proximal nuclei (such as the adjacent arcuate nucleus (ARC)),
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Figure 2 Electolytic Lesioning of the VMH causes Hyperphagia and Obesity
(Right) Rat with bilateral VMH lesions produced using a Horsley-Clark stereotaxic
apparatus develops hyperphagia and massive obesity. (Left) Control rat. Adapted
from Hetherington and Ranson, 1940.

or possibly white matter tracts passing through the region (Gold, 1973). Further research,
though, would more concretely verify the role of the VMH in feeding and body weight
regulation, and provide evidence for the involvement of the VMH in a number of
metabolically related functions.
To overcome the criticisms of the electrolytic lesioning work, investigators took
advantage of chemicals to produce more specific lesions. Lesions induced by ibotenic
acid produce the same phenotypes as electrolytic lesions, but with much less non-specific
damage (Grossman et al., 1978; Shimizu et al., 1987). Also, gold-thiogluocose, when
administered intraperitoneally to mice and rats, produces hyperphagia and massive
obesity secondary to lesions of the VMH (Marshall et al., 1955; Marshall and Mayer,
1956).
Perhaps the most specific VMH lesion is that which fortuitously resulted from
targeted deletion of the gene Steroidogenic factor-1 (SF-1). SF-1 is an orphan nuclear
receptor, originally identified as a binding factor to a 5’ flanking sequence common to a
number of the cytochrome P450 steroid hydroxylases (Lala et al., 1992; Parker et al.,
2002). SF-1 knockout mice suffer from adrenal and gonadal agenesis and gonadotrope
disfunction, leading to death during the first week of birth from adrenal insufficiency
(Ingraham et al., 1994; Luo et al., 1994).

Rescue of these mice with exogenous

corticosteroids and adrenal transplants resulted in a maturity onset obesity phenotype
characterized by normophagia in the context of significantly reduced energy expenditure
(Majdic et al., 2002). Examination of the hypothalamus of these animals reveals a
significantly disordered VMH (Ikeda et al., 1995). Initially termed “VMH agenesis”, in
reality these mice have VMH neurons, as monitored by lineage tracing using an SF-1-
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EGFP transgene, but these neurons fail to coalesce into their proper location and
architecture during development, instead remaining spread throughout the hypothalamus
(Davis et al., 2004). These neurons also fail to terminally mature in the absence of SF-1
(Tran et al., 2003).
A number of studies have implicated the VMH as a central player in glucose
homeostasis. A glycemic-clamp study showed that ibotenic acid-induced lesions to the
VMH, but not the LH, specifically interfered with an important physiological
counterregulatory response to hyperglycemia, characterized by increased release of
glucagon from the pancreas and catecholamines from the adrenal gland (Borg et al.,
1994). Subsequently, infusion of a glucose analog, 2-deoxyglucose, into the VMH of rats
via cannula was found to be sufficient to cause counterregulatory hormone release in the
context of systemic normoglycemia (Borg et al., 1999). Local perfusion of glucose into
the VMH was also capable of blocking the response in hypoglycemic rats (Borg et al.,
1997). The ability of the VMH to sense and respond to systemic glucose levels is
attributable to its large population of glucose sensing neurons. By some estimates, as
many as 60% of VMH neurons are either activated by or inhibited by increased glucose
concentrations (Kang et al., 2004).
A number of molecules are implicated in glucosensing in the VMH.

In an

analogous system to pancreatic beta cells blood glucose monitoring, involvement of the
low-affinity glucose transporter GLUT2 and the glucose-phosphorylating enzyme
glucokinase have been suggested. Consistent with this possibility, the expression of both
GLUT2 and a glucokinase isoform have been reported in the VMH (Leloup et al., 1994;
Lynch et al., 2000). Glucokinase has been shown to be a very good predictive marker for
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glucosensing ability by VMH neurons (Kang et al., 2004). ATP-sensitive potassium
channels have also been implicated in glucose sensing, as they offer a means to couple
membrane potential to internal cell metabolism (Ashford et al., 1990a, b). Targeted
deletion of the KATP channel Kir6.2 resulted in normoglycemic mice that displayed
severely blunted glucagon release following hypoglycemia imposed by insulin
administration (Miki et al., 2001). By electrophysiological analysis, VMH neurons from
these mice were not responsive to glucose.
These studies all clearly showed a significant role for the VMH, and by extension
the hypothalamus, in the regulation of food intake, body weight, and metabolism.
However, fundamental questions about the hypothalamic control of food intake remained
unanswered. Specifically, it remained entirely unclear how the hypothalamus accounted
for peripheral energy stores, and how this information was incorporated into feeding
decisions. This type of accounting would have to be a critical component of any model
attempting to explain the exquisitely tight regulation of body weight observed in both
animals and humans.

Leptin
In the summer of 1949, a spontaneous mutation was observed in the V mouse
stock at Jackson Laboratories. Mice homozygous for this recessive mutation, obese (ob)
were more than three times the weight of their unaffected littermates at 10 months of age,
the result of massive hyperphagia and reduced energy expenditure (Fig. 3) (Ingalls et al.,
1950). Additionally, these mice displayed sterility, insulin resistance, and significant
disturbances in hormonal axes and thermoregulation (Batt and Mialhe, 1966). In 1966,
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a

b

Figure 3 Mutation of the Obese (ob) Gene Causes Profound Obesity
(a) Normal control (12g) and ob/ob mouse (16g) at 3 weeks of age. (b) Normal control
(29g) and ob/ob mouse (90g) at 10 months of age. Adapted from Ingalls et al. 1950.

another spontaneously obese strain arose, displaying a similar adiposity phenotype to the
ob/ob mouse. However, this mouse was more hyperglycemic and insulin resistant, and
was thus given the name diabetes (db) (Hummel et al., 1966).
Because of the similarity of the two phenotypes, it was thought that the two
mutations might play a role in the same pathway, and indeed the differences between the
two phenotypes were shown to be largely the result of background strain effects
(Coleman and Hummel, 1973). This supposition was greatly supported and expanded
upon by classic parabiosis studies performed by Coleman. In these experiments, mice
were literally stitched together to promote the formation of a shared circulatory system.
When ob/ob mice were parabiosed to wild-type control mice, they reduced their food
intake to that of their parabiosed partners. The same was not observed for db/db mice
when parabiosed to normal mice or ob/ob mice (Coleman, 1973). Instead, parabiosed
partners of db/db mice, whether they were normal or ob/ob mice, would reduce their food
intake, becoming hypoglycemic and dying of starvation (Coleman and Hummel, 1969).
The experiments suggested the existence of a powerful negative feedback system
regulating food intake, mediated by a factor circulating in plasma. Additionally, Coleman
hypothesized that the ob/ob mouse was deficient in its ability to produce this factor, while
the db/db mouse lacked the ability to respond to the factor. Two decades later, he was
proven correct.
The positional cloning of the ob gene in 1994 represented an enormous
breakthrough for molecular obesity research (Zhang et al., 1994). The product of the ob
gene is a 16kd (167 amino acid) secreted protein, named leptin. The original obese
mouse, ob/ob1j, was shown to bear a nonsense mutation, resulting in a truncated, non-
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functional protein. Consistent with the results of the parabiosis studies, leptin was shown
to dramatically inhibit feeding in ob/ob and wild-type mice upon IP administration,
whereas it had no effect on db/db mice . Indeed, leptin administration was able to correct
nearly all of the abnormalities of the ob/ob mouse, including the food intake, weight,
energy expenditure, fertility, and insulin resistance phenotypes (Campfield et al., 1995;
Halaas et al., 1995; Pelleymounter et al., 1995). Interestingly, mice treated with leptin
lost significantly more weight than pair-fed control mice, indicating that leptin has a
significant effect on metabolism separate from its impact on food intake (Levin et al.,
1996).

Leptin is produced and excreted predominantly by adipose tissue, though

expression is also seen in the placenta, gastric epithelium, and skeletal muscle (Masuzaki
et al., 1997; Bado et al., 1998; Wang et al., 1998). Plasma leptin is undetectable in ob/ob
mice, whereas in db/db mice the levels are massively elevated. In normal mice and
humans, leptin levels are roughly correlated with adipose tissue mass (Maffei et al., 1995;
Zachwieja et al., 1997). Thus, circulating leptin levels represent an accurate read-out of
aggregate energy storage.

Leptin Receptor
Once leptin was discovered, it was used as a tool by Tartaglia et al. to identify its
own receptor (Tartaglia et al., 1995).

The group made several leptin-alkaline

phosphatase fusion constructs (as well as I125Leptin), and used them to screen a variety of
cell lines and tissue samples. Choroid plexus was identified as having a high affinity for
leptin, and a cDNA library was constructed from this tissue. Subsequent screening of this
library for binding to the leptin receptor fusion constructs led to the identification of the
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receptor for leptin, Ob-R.

Ob-R is a single membrane-spanning receptor, sharing

significant homology with the gp130 signal-transducing component of the IL-6 receptor,
G-CSF receptor, and LIF receptor, making it a member of the class I cytokine receptor
family (Tartaglia et al., 1995).
There at least six spliceoforms of the leptin receptor (Ob-Ra – Ob-Rf), each of
which differs only with regards to the C-terminal portion (Lee et al., 1996).

The

extracellular portion of all six receptor forms is identical. Of the six, only the Ob-Rb
variant possesses the full spectrum of intracellular signaling components, including JakStat binding motifs and three tyrosines that, when phosphorylated, activate SH2containing proteins. Following the cloning of Ob-R, it was discovered that the original
C57Bl/K db mutant bore a premature stop codon that affected only the Ob-Rb isoform
(Lee et al., 1996). Because the phenotype of the original mutant was indistinguishable
from that of other later-discovered db mutants that were defective in the production of all
six isoforms, it was reasoned that the Ob-Rb isoform was of pivotal importance for
leptin-responsive signal transduction.
The various leptin receptor isoforms are widely expressed throughout the body,
but the long variant, Ob-Rb, is expressed most strongly in the hypothalamus, and in the
very same nuclei that had previously been implicated by lesioning studies to play a role
in the regulation of food intake and body weight (Lee et al., 1996). In situ hybridization
with an Ob-Rb specific probe showed strong expression in the ARC, VMH, LH,
dorsomedial hypothalamic nucleus (DMH), and ventral premammillary nucleus, and to a
somewhat lesser extent in the periventricular nucleus (Mercer et al., 1996; Fei et al.,
1997; Elmquist et al., 1998).
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When leptin and its receptor were discovered, it was hoped that leptin would
represent a miracle cure for obesity. However, it turned out that most obese humans
already had high levels of plasma leptin, indicating resistance to leptin’s effects
(McGregor et al., 1996). The same was found to be the case for high-fat diet-induced
obese animals (Frederich et al., 1995). This concept of leptin resistance is still not fully
understood, nor is it known whether, in humans, leptin resistance is a primary failing or a
byproduct of adiposity. This unexpected discovery represents a transitional point in
obesity research. The work of many different subfields of obesity research have been
unified by the discovery of the elegant leptin feedback loop, answering many of the
fundamental questions about how the body performs energy accounting. But, at the same
time, the surprising findings regarding leptin resistance served to highlight how little was
still known about both the mechanism of entry of leptin into the brain as well as the
complex neuronal circuitry that must integrate and process such information in order to
produce feeding decisions.

Leptin Signaling
The leptin receptor appears to exert its effects through a number of different
intracellular signaling pathways (Fig. 4). As previously mentioned, the long form of the
receptor, Ob-Rb, is a member of the class I cytokine receptor family, whose members
possess cytoplasmic Box 1 and Box 2 domains that are involved in the recruitment of
Janus kinases (JAKs) (Ihle and Kerr, 1995; Kloek et al., 2002). Upon binding of leptin to
its receptor, the receptor oligomerizes, leading to the recruitment and crossphosphorylation of JAK2 proteins, which subsequently phosphorylate tyrosine residues
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Ob-Rb

Figure 4 Overview of Intracellular Leptin Receptor Signaling
Binding of leptin to the long form of the leptin receptor (Ob-Rb) causes activation of Jak2
molecules associated with the Box 1 domain of the receptor. Activated Jak2 phosporylates
tyrosines 985 and 1138 on the receptor. Signal transducer and activator of transcription 3
(Stat3) binds pY1138, leading to Stat3 phosphorylation, activation, and nuclear translocation. pStat3 causes increased expression of POMC and SOCS3 mRNA, and depresses
the expression of AgRP mRNA. pY985 recruits SHP-2, which becomes phosphorylated
and binds Grb-2, leading eventually to activation of extracellular signal-regulated kinase
(ERK). After prolonged receptor stimulation, an unidentified event allows the inhibitory
molecule SOCS3 to bind to the receptor at pY985, where it interferes with signal
transduction. Signals mediated via unidentified tyrosine phosphorylation sites on Ob-Rb
include the tyrosine phosphorylation of insulin receptor substrate (IRS) proteins (leading to
activation of the phosphoinositol-3-kinase (PI3K) pathway) and a minor component of ERK
activation. Adapted from Myers 2004.

on the receptor (at positions 985, 1077 and 1138) (Ghilardi and Skoda, 1997; Nakashima
et al., 1997; White et al., 1997). Tyr1138 has been shown to be crucial for the subsequent
recruitment of the Src-homology 2 (SH-2) domain-containing STAT (signal transducer
and activator of transcription) proteins (Ghilardi et al., 1996; Bjorbaek et al., 1997).
STAT proteins, once bound to phospo-tyrosine residues, are then phosphorylated by
JAKs, leading to STAT dimerization and transport to the nucleus, where they activate
transcriptional programs (Schindler, 1999). Of the STAT proteins, the one most closely
associated with leptin receptor signaling is STAT3. STAT3 phosphorylation has been
observed in the hypothalami of both wild-type and ob/ob, but not db/db, mice following
leptin administration (Vaisse et al., 1996). Interestingly, when Tyr1138 of the leptin
receptor was replaced with a serine reside via a knock-in approach, an interesting mixed
phenotype was observed. The Ser1138 animals were hyperphagic and obese, like db
mice, but were not infertile (Bates et al., 2003).

Additionally, they were less

hyperglycemic and exhibited normal body length, different from the stunted growth
observed in the db animal. This suggests that STAT3 activation is required for leptindependent energy homeostasis, but that a separate leptin receptor dependent signaling
pathway or pathways are utilized for control of fertility, lean body growth, and glucose
homeostasis.
Other intracellular signaling pathways have been implicated in the response to
leptin.

The phosphatidylinositol-3-OH (PI3) kinase pathway has been shown to be

activated in vivo by leptin administration (Kellerer et al., 1997), and icv administration of
a PI3K inhibitor significantly attenuated the anorexic effect of leptin administration
(Banks et al., 2000). In a number of cell culture studies, binding of leptin to its receptor
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has been documented to activate the mitogen-activated protein kinase (MAPK) pathway
(Bjorbaek et al., 1997; Takahashi et al., 1997). Subsequently, it was shown that MAPK
is phosphorylated in the hypothalamus in response to leptin, and that this process requires
the action of the phosphatase SHP-2, which can dock at phosphotyrosine 985 of Ob-Rb
(Banks et al., 2000). It is unknown what in vivo function is played by the MAPK
pathway with regards to the response to leptin, but this pathway is implicated in the
upregulation of c-fos, a marker of neuronal activation which is upregulated in response to
leptin stimulation (Bjorbaek et al., 2001). By electrophysiological examination, leptin
has also been found to hyperpolarize leptin-responsive neurons in the Arc and VMH via
the actions of an ATP-sensitive potassium pump (Spanswick et al., 1997).

The

mechanism of activation of this pump is not clear.
Leptin signaling is specifically inhibited by a couple of known pathways. The
expression of suppressor of cytokine signaling 3 (SOCS3) is specifically upregulated in
leptin-responsive Arc and DMH neurons of WT and ob/ob, but not db/db, mice in
response to leptin (Bjorbaek et al., 1998). Additionally, in DIO mice, SOCS3 was found
to be upregulated in the Arc (Munzberg et al., 2004). SOCS3 has been shown in cell
culture to interfere with leptin signaling by binding to phosphotyrosine 985 of the Ob-Rb
(Bjorbaek et al., 2000). Another molecule, protein-tyrosine phosphatase 1B (PTP1B),
has been shown to negatively regulate leptin signaling. PTP1B is expressed in some of
the same nuclei as Ob-Rb, including the Arc and VMH, and in cell culture, PTP1B
selectively dephosphorylates JAK2 (Cheng et al., 2002; Zabolotny et al., 2002). PTP1B /- mice are resistant to obesity, displaying hypersensitivity to leptin treatment and
resistance to diet-induced obesity (Elchebly et al., 1999; Klaman et al., 2000). Because
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of their ability to specifically interfere with leptin signaling in the hypothalamus, both
SOCS3 and PTP1B have been strongly implicated in the development of leptin
resistance.

Neuropeptides
Recent research has been revealing an ever expanding, complex set of
neuropeptides that are expressed in various hypothalamic nuclei, some of which are
implicated in the regulation of food intake. What follows is a brief overview of what has
become a vast and complicated field of research.
Melanin concentrating hormone (MCH), a cyclic 19 amino acid peptide originally
studied for its ability to concentrate melanin in the melanophores of fish species (Wilkes
et al., 1984), is expressed in the LH and zona incerta of the rodent hypothalamus
(Skofitsch et al., 1985; Bittencourt et al., 1992), where it is now regarded as having a
significant impact on food intake. MCH mRNA is expressed at elevated levels in the
hypothalami of ob/ob mice, compared with ob/+ controls (Qu et al., 1996). It is also
elevated in fasted mice, compared with control mice fed ad libitum.

Additionally,

injection of MCH peptide into the lateral ventricles of rats led to significantly increased
food intake (Qu et al., 1996). Targeted deletion of the MCH gene results in mice which
display leanness resulting from decreased food intake and increased energy expenditure,
despite decreased levels of leptin, certifying this orexigenic peptide as a downstream
target of the leptin pathway (Shimada et al., 1998).
Two MCH receptors have been currently identified. The first was a previously
orphan G-protein coupled receptor (GPCR), SLC-1, now referred to as MCHR1
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(Chambers et al., 1999; Lembo et al., 1999).

MCHR1 is widely expressed throughout

the CNS, and within the hypothalamus, MCHR1 is localized to numerous nuclei,
including the LH, ARC, VMH and DMH (Lembo et al., 1999; Hervieu et al., 2000).
MCHR1-/- mice are roughly normal weight, but are lean with reduced fat mass (Chen et
al., 2002; Marsh et al., 2002). These mice are also hyperphagic, but this hyperphagia is
offset by increased energy expenditure. After the discovery of the first MCH receptor,
another similar receptor, MCH2R was cloned (An et al., 2001; Hill et al., 2001).
However, this receptor may not be as physiologically relevant, as many non-human
mammals (including rat, mouse, hamster, guinea pig, and rabbit) either do not express
functional MCHR2 receptors, or express a non-functional MCHR2 pseudogene (Tan et
al., 2002).
The orexins (orexin-A and orexin-B), also referred to as the hypocretins, are
another important neuropeptide type expressed in the LH along with MCH, but in a
mutually exclusive group of neurons (Broberger et al., 1998). The orexins are short
peptides, which originate from the same precursor molecule, Prepro-Orexin (de Lecea et
al., 1998). Like MCH, icv administration of orexin peptides leads to a significant dosedependent induction of food-intake (Sakurai et al., 1998). Prepro-Orexin mRNA levels
are increased by fasting, but were observed to be downregulated in ob/ob and db/db
hypothalami by in situ hybridization, indicating that their regulation is different from that
of MCH (Yamamoto et al., 1999; Yamamoto et al., 2000). Targeted deletion of the
Prepro-Orexin gene results in a phenotype similar to human and canine narcolepsy
(Chemelli et al., 1999).

This suggests that the orexins are really modulators of

sleep/wake states and alertness. Prepro-Orexin knockout animals are of normal body
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weight, though they do display hypophagia.

Transgenic mice in which the orexin

neurons are ablated by expression of a truncated Machado-Joseph disease gene product
(ataxin-3) display similar phenotype to the Prepro-Orexin knockout, displaying
narcolepsy and hypophagia, but these mice actually develop late-onset obesity despite the
hypophagia (Hara et al., 2001). There is ample evidence that the orexins are involved in
both sleep/wake/alertness as well as energy homeostasis, revealing an interesting,
complex link between these two systems.
Two orexin receptors have been identified (OX1R and OX2R), which were both
previously orphan GPCRs (Sakurai et al., 1998). They display broad and somewhat
overlapping patterns of expression within the CNS, and are expressed highly in
hypothalamic nuclei implicated in energy homeostasis. Within the hypothalamus, OX1R
is mostly restricted to the VMH and DMH, while OX2R mRNA is expressed mainly in
the Arc, VMH, DMH, and paraventricular nucleus (PVN) (Trivedi et al., 1998; Lu et al.,
2000).
Taken together, the mutually exclusive orexin and MCH neuronal populations
within the LH display all of the properties of the LH feeding center predicted from the
original lesioning studies (Elmquist et al., 1999). This refinement of a processing center
into its genetically defined component neuronal populations is a common theme of recent
progress towards the elucidation of leptin-responsive pathways in the CNS.
Neuropeptide Y (NPY) is a 36 amino acid peptide that shares significant
homology with the gut peptides pancreatic polypeptide and peptide YY (Tatemoto et al.,
1982). NPY is widely expressed throughout the brain, and is expressed strongly in the
Arc, where it is found in neurons that express the leptin receptor (Allen et al., 1983).
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NPY has been implicated in, among other things, hypothalamic-pituitary signaling
(Colmers and Wahlestedt, 1993), cardiovascular physiology (McDermott et al., 1993),
sympathetic nervous system function (Stjarne et al., 1986), and modulation of mood
(Wahlestedt et al., 1993). Notably, icv administration of NPY peptide into rats produces
a significant increase in feeding (Clark et al., 1984), while long-term infusion actually
results in obesity (Zarjevski et al., 1993). Fasted mice, as well as ob/ob and db/db mice,
display elevated levels of NPY mRNA in the Arc (Wilding et al., 1993). Significant
reduction in hypothalamic NPY mRNA and NPY release are observed following
treatment with IP or icv leptin (Stephens et al., 1995; Schwartz et al., 1996b).
Interestingly, though the data supports a central role for NPY in processing and
transmission of the leptin signal, mice with targeted deletion of the NPY gene show only
the mildest phenotype related to energy homeostasis (Erickson et al., 1996b). NPY
knockout mice are of normal size and weight. However, these mice do display slight
hypersensitivity to treatment with leptin, eating less and losing more weight during the
first two days of chronic leptin treatment than WT control mice.

However, by day 5,

total weight loss between the two groups was identical. NPY -/- mice also displayed
slightly stunted re-feeding responses following a 2-day fast. However, this effect was
also short-lived, and none of these effects were observed without substantial backcrossing onto C57Bl6 background. A more significant phenotype was observed when
NPY -/- mice were bred onto an ob/ob background. The resulting mice displayed
significant attenuation of all aspects of the ob/ob phenotype, with reduced adiposity and
food intake and improved fertility, diabetes, and energy expenditure.

(Erickson et al.,

1996a). This data clearly establishes NPY as an important mediator of all of the
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physiological effects of leptin. However, the lack of severity of the knockout phenotype
is still puzzling.
The neuropeptide Y family members (NPY, peptide YY (PYY), and pancreatic
polypeptide), bind to the Yx family of GPCRs (Y1 through Y5 and PYY-preferring
receptor). A study of the pharmacological profiles of various receptor agonists suggested
that the Y5 receptor was the most likely to mediate the orexigenic effect of icv NPY
administration (Gerald et al., 1996).

However, Y1-/- and Y5-/- mice have been

generated, and display minimal metabolic phenotypes aside from mild late-onset obesity
(Kushi et al., 1998; Marsh et al., 1998). Intriguingly, chronic icv administration of NPY
to Y1-/- or Y5-/- mice produced equivalent hyperphagia and weight gain to that observed
in NPY-treated WT mice (Raposinho et al., 2004). Thus, there remains uncertainty
regarding the true effector/effectors of NPY action. It is likely that there is significant
redundancy between the receptors, and that at the very least, receptors Y1 and Y5 work
together to transduce signals from icv injected NPY. The Y1, Y2, Y4, and Y5 receptor
subtypes are all abundantly expressed in hypothalamic feeding nuclei, with considerable
overlap between Y1 and Y5 expression, enforcing the theory of redundancy and
cooperation between these receptors (Gustafson et al., 1997; Jacques et al., 1998; Parker
and Herzog, 1999; Kishi et al., 2005).
Over the years, a number of spontaneous mutations have been observed which
result in yellow coat color, obesity, diabetes, and increased susceptibility to cancer.
These include the lethal yellow (Ay) and viable yellow (Avy) mutations, which are alleles
of the agouti (A) locus (Dickies, 1962, 1969). Agouti is named after the banding pattern
of the South American rodent of the same name. Cloning of the agouti gene revealed
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that it is a 131 amino acid paracrine signaling factor, produced in hair follicles, that acts
at melanocortin 1 receptors (MC1R) on melanocytes in order to inhibit eumelanin (black)
production in favor of production of pheomelanin (yellow) (Furumura et al., 1996). In Ay
and Avy mice, agouti is constitutively produced in the hair follicles, (where its
constitutive inhibition of MCR1 produces pure yellow fur), as well as in many other
tissues. In the brain, this excess agouti protein acts at other melanocortin receptors,
MC3R and MC4R, which are present at high levels in the hypothalamus, and this
interaction is the cause of the obesity phenotype of these animals (Mountjoy et al., 1994;
Lu et al., 1994; Klebig et al., 1995).
A search was conducted to find expressed sequence tags (ESTs) related to agouti,
resulting in the identification of a transcript that produces another 131 amino acid protein
with 25% homology to agouti.

Agouti-related peptide (AgRP, or agouti-related

transcript, ART) is expressed predominantly within the Arc, median eminence, and
adrenal medulla in mice, and within the Arc, AgRP shows completely overlapping
expression with NPY (Shutter et al., 1997; Hahn et al., 1998). AgRP mRNA expression
in the Arc is approximately 10-fold elevated in ob/ob and db/db mice. AgRP was found
to inhibit melanocortin action selectively at melanocortin 3 and 4 receptors, with 100-fold
more potency than agouti protein (Fong et al., 1997; Ollmann et al., 1997).
Mice with targeted deletion of the AgRP gene, like NPY knockout mice, have
little or no observable phenotype. AgRP-/- mice display normal food intake, growth
curves, energy expenditure, and body composition (Qian et al., 2002). It was thought that
perhaps AgRP and NPY play redundant functions within Arc neurons, and so the Agrp
and NPY knockout mice were bred together to create AgRP-/-; NPY-/- double mutants.
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Strikingly, there was no additive effect of double mutation, and AgRP-/-; NPY-/- mice
were not shown to have any severe metabolic abnormalities (Qian et al., 2002). The bulk
of the data still suggests an important role for these peptides in feeding, but in that case
the redundancy inherent to the hypothalamic energy homeostatic system is extremely
robust.
The biology of the agouti protein and its relative, AgRP, clearly implicated the
melanocortin system as a central component of the system that regulates food intake and
body weight. The melanocortins, adrenocorticotropin (ACTH) and the alpha, beta, and
gamma melanocyte-stimulating hormones, are implicated in an extremely diverse set of
biological functions, precluding a full summary (Strand, 1999).

Implication of the

melanocortins in body weight regulation was first suggested by a study showing a
significant reduction in spontaneous feeding following icv injection of ACTH(1-24)
(Poggioli et al., 1986). Of the remaining melanocortins, icv administration of alpha- and
beta-MSH produces a significant inhibitory effect on post-fast feeding in rats, whereas
gamma-MSH has no effect (Abbott et al., 2000). All four melanocortins are cleaved
from a single precursor protein, pro-opiomelanocortin (POMC). Hypothalamic POMC
mRNA is reduced by fasting, and is upregulated in response to leptin treatment, and
ob/ob and db/db show reduced levels of hypothalamic POMC expression (Mizuno et al.,
1998a). Within the hypothalamus, POMC mRNA is expressed highly in the Arc, and
subsequent work showed that POMC and NPY/AgRP are expressed in mutually
exclusive populations of neurons within the Arc (Elias et al., 1999). This separation
between the orexigenic and anorexigenic peptides in the Arc suggests the possibility of
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negative feedback between the two systems, which will be discussed in more detail in the
following section.
The melanocortins act through a family of five G-protein coupled receptors
(MC1R through MC5R) (Adan and Gispen, 1997).

In the hypothalamus, the

predominant receptor forms are MC3R and MC4R (Roselli-Rehfuss et al., 1993;
Mountjoy et al., 1994), and it is MC4R that is most intimately connected with the
regulation of feeding, as both alpha- and beta-MSH act largely at this receptor (Abbott et
al., 2000). MC4R knockout mice display a striking metabolic phenotype, developing
maturity-onset obesity in the context of hyperphagia, hyperinsulinemia, and
hyperglycemia (Huszar et al., 1997). This mouse largely recapitulates the metabolic
phenotype of the obese agouti mutants, supporting the model that the obesity in these
mice is the result of chronic MC4R antagonism. Because gamma-MSH acts primarily at
MC3R and has no significant effect on feeding, it was postulated that this receptor would
not be critically involved in this pathway (Abbott et al., 2000). Indeed, while MC3R
knockout mice do display a modest increase in fat mass and a concomitant decrease in
energy expenditure, the phenotype of these mice is far less striking than that of the MC4R
knockout (Butler et al., 2000).
Cocaine and amphetamine-regulated transcript (CART) is a potent anorexigenic
peptide, discovered via a PCR differential display screen for genes upregulated by these
psychomotor stimulants (Douglass and Daoud, 1996).

CART is widely expressed

throughout the CNS, and in the hypothalamus it is expressed strongly within the Arc and
DMH (Kristensen et al., 1998).

Fasted mice show reduced levels of Arc CART

expression, and in ob/ob and db/db mice Arc CART expression is almost completely
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absent. icv infusion of CART peptide into rats inhibits both normal and post-fasting food
intake (Kristensen et al., 1998). Interestingly, in the Arc, CART was found to be almost
totally colocalized with POMC, indicating that this molecule most likely has its influence
on energy homeostasis at the same level of the pathway as the melanocortins (Elias et al.,
1998a).
There are a number of other neuropeptides that are implicated in the central
regulation of feeding, but not to the degree of those described above. Two related
peptides, galanin and galanin-like peptide (GALP), are both expressed in feeding nuclei
(Skofitsch and Jacobowitz, 1985; Ohtaki et al., 1999; Larm and Gundlach, 2000),
including the Arc, and central administration of both peptides stimulates feeding in
rodents (Kyrkouli et al., 1986). Whereas chronic injection with NPY, for example,
produces a long-term change in body weight, the same is not the case for galanin (Smith
et al., 1994). Nevertheless, the discovery that some galanin- and GALP-expressing
neurons in the Arc also express the leptin receptor and modulate their level of
galanin/GALP mRNA in response to leptin treatment has led to renewed interest in these
peptides (Hakansson et al., 1998; Sahu, 1998; Jureus et al., 2000).

Corticotropin-

releasing hormone (CRH) is expressed in the paraventricular, supraoptic, medial and
periventricular preoptic, and premammillary nuclei of the hypothalamus (Merchenthaler
et al., 1982). CRH neurons in the paraventricular nucleus project to the pituitary, where
they regulate the excretion of ACTH, a key regulator of adrenal cortisol production
(Cone, 2000). icv injection of CRH causes a significant reduction in food intake (Gosnell
et al., 1983). Neuromedin U (NMU) is a neuropeptide produced mainly within the Arc in
the hypothalamus in neurons that also express the leptin receptor. icv administration of
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NMU sharply reduces food intake, and injection of an anti-NMH antibody increases food
intake (Howard et al., 2000; Kojima et al., 2000). NMU knockout mice display obesity,
hyperphagia, and decreased food intake and energy expenditure (Hanada et al., 2004).
Interestingly, administration of exogenous leptin led to reduced adiposity, suggesting that
NMU may act, at least in part, via a leptin-independent pathway.

Marker Genes and the Leptin Feeding Circuit
Clearly, this bewildering array of neuropeptides is integrally involved in
the regulation of food intake and energy homeostasis, but the diverse expression profiles
of these peptides and their receptors within the hypothalamus suggest a much deeper
level of complexity at the level of neuronal organization and integration. It has become
apparent that classical models of feeding regulation based on antagonistic
phamacological properties of neuropeptides are fundamentally insufficient, in that they
provide little foundation upon which to build complex models of neuronal circuitry. In
order to begin to understand the operation of a complex neuronal circuit, the first step
must be to define the component players and understand how they are interconnected.
Thus, discrete neuronal cell types of interest must be identified, catalogued, and studied.
From such studies identifying functional components, a working model may then be
created that would be robust enough to allow for further refining and further integration
of new components.
Schemes for defining neuronal cell types were historically based on neuronal
morphology. For example, neurons in the PVN and many other nuclei are commonly
broken down into magnocellular and parvocellular groups, etc (Armstrong et al., 1980).
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However, morphology is an extremely blunt tool with which to dissect the differences
between neurons. Recently, it has emerged that discriminating neuronal cell types on the
basis of gene expression may be the most powerful and functionally relevant method.
For example, within the ARC are two mutually exclusive groups of neurons, the
NPY/AgRP and POMC/CART subpopulations. These populations of neurons express
neuropeptide sets known to be functionally antagonistic, and yet these two groups of
neurons cannot be differentiated on the basis of size, localization, or morphology.
Indeed, it is through intensive study of these very two populations, defined on the basis of
gene expression, that most of the recent progress towards understanding this system has
been made.
Because the NPY/AgRP and POMC/CART neurons express neuropeptides with
opposing pharmacological function, it was assumed that these populations of neurons
would have antagonistic functions. However, both populations were found to express
significant amounts of the long form of the leptin receptor, Ob-Rb, which at first glance
appeared paradoxical. However, this was resolved when it was observed that treatment
with leptin activates only the POMC neurons, as measured by the expression of the
activation marker c-fos (Elias et al., 1999). Presumably, leptin inhibits NPY/AgRP
neurons, as NPY mRNA levels drop following leptin treatment, while the expression of
POMC is increased in POMC/CART neurons (Schwartz et al., 1996a). Thus, leptin acts
as a tuner, modulating the activity of these two important populations of neurons. But, if
that is the case, and the interplay between these groups are responsible for regulation of
feeding, how do they exert their downstream effects?
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ARC NPY/AgRP and POMC/CART neurons both project to the same regions,
among them the LH and the PVN (Kiss et al., 1984; Elias et al., 1999). At downstream
sites expressing the MC4 receptor, these projections exert their opposing influence, and
their relative contributions are integrated (Elmquist, 2001). The PVN is recognized as
perhaps the major output center of the hypothalamus. The PVN expresses a number of
hormones (including CRH, thyrotropin releasing hormone (TRH), and oxytocin), and has
dense projections to the pituitary, where it is a major regulator of hormone release
(Kandel and Schwartz, 1991).

The PVN is also heavily implicated in signaling to

autonomic centers. In fact, two anatomically and functionally segregated groups of
neurons within the PVN are responsible for significant outputs to both sympathetic and
parasympathetic nervous system centers (Buijs et al., 2003). In the PVN, the same
neurons that express the MC4 receptor and receive inputs from Arc NPY/AgRP and
POMC/CART neurons also express pre-TRH RNA (Legradi and Lechan, 1999; Fekete et
al., 2000a; Fekete et al., 2000b). This suggests that some of the metabolic effects of
leptin are attributable to modulation of the hypothalamic-thyroid axis.
In the LH, both the orexin and MCH expressing neuronal subtypes receive dense
innvervation by NPY/AgRP and alpha-MSH containing fibers (Broberger et al., 1998;
Elias et al., 1998b). Because AgRP expression in the CNS is localized exclusively to the
Arc, the NPY/AgRP fibers clearly originate from there.

Additionally, stereotaxic

injection of the retrograde tracer fluorogold into the LH led to positive staining of both
NPY/AgRP and POMC/CART neurons in the Arc (Elias et al., 1999). Both the MCH
and orexin neuronal populations in the LH project to a wide range of intra- and extrahypothalamic sites, including autonomic system centers and to the cortex (Saper et al.,
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1976b; Saper, 1985; Saper et al., 1986). According to a model proposed by the authors,
these cortical projections might represent an important link between this largely
unconscious regulatory system and consciousness itself.

An overview of proposed

hypothalamic feeding circuitry connections is shown (Fig. 5).
This initial data regarding the NPY/AgRP and POMC/CART neurons confirmed
the utility of approaching this circuitry problem from the perspective of discrete neuronal
subtypes defined on the basis of gene expression.

Interestingly, as a result of this

approach, the ability of the neuropeptides to label discrete neuronal populations has
become far more valuable to researchers than their pharmacological activities. In fact,
because of the multitude of neuropeptide knockouts with minimal or no phenotype, it
seems likely that neurons are much more than just the sum of the neuropeptides that they
express.

It stands to reason then that neurons do not need to express a

pharmacologically-validated feeding peptide to be critically involved in the leptinresponsive circuit. Such neurons may be just as important, and a gene that is specifically
expressed in that neuronal compartment, which can be used to mark or label those
neurons and not surrounding neurons, may be as important as a neuropeptide to the
overall task of developing a working model of the circuit.
The experiments described above utilized the marker genes to label their
component neurons by either immunohistochemistry or in situ hybridization. However,
these techniques represent only the tip of the iceberg as far as the utility of the marker
genes is concerned. Their true value is in their use as genetic tools to express transgenes
of interest specifically to the cell types that they label, by hijacking the promoter
elements of the markers themselves. This strategy has been used to learn substantially
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Figure 5 Proposed Wiring Diagram of Hypothalamic Feeding Circuitry
Pathways inhibited by leptin, and thus presumably anorexic, are indicated
by red arrows. Pathways activated by leptin (presumably phagic) are denoted
by green arrows. Circadian inputs are denoted by dashed blue lines. OC,
optic chiasm; SCn, suprachiasmatic nucleus; SPV, subparaventricular zone;
PVH, paraventricular hypothalamic nucleus; DMH, dorsomedial hypothalamic
nucleus; VMH, ventromedial hypothalamic nucleus; ARC, arcuate nucleus;
LHA, lateral hypothalamic area. Adapted from Elmquist et al. 1999.

more about populations of interest in the hypothalamic feeding circuit, as discussed
below.
Transgenic and knock-in mice expressing transgenes in specific component
neuronal populations within the feeding circuitry have proved themselves to be
invaluable tools for assaying not only the biology of these neurons, but also the
connectivity, function, and plasticity of the circuit as a whole. For example, knock-in
mice expressing cre recombinase in Ob-Rb neurons (Ob-Rb cre mice) have been used in
elegant tracing experiments utilizing a conditional strain of pseudorabies virus to map the
multi-synaptic inputs to leptin receptor neurons within the ARC (DeFalco et al., 2001).
This study highlights the extraordinary potential for using such mice in conjunction with
conditional tracing methods to generate an extremely detailed circuitry map for this
system. While PRV infects primarily in a retrograde manner via synaptic connections
(Strack et al., 1989b), highlighting inputs to neurons of interest, there is no reason the
cre/lox strategy could not also be applied to anterograde tracers, such as lectins or wheatgerm agglutinin (Braz et al., 2002).
Because knock-in mice are difficult and slow to generate, recent efforts have
focused on transgenic methods to express transgenes under the control of marker gene
promoters. While traditional transgenic constructs, in which sections of 5’ flanking DNA
are inserted upstream of transgenes to drive expression, have been used to drive the
expression of transgenes, the resulting expression is highly sensitive to positional effects
(Yang et al., 1997). Additionally, distal enhancers and repressor sequences are often
absent, leading to incorrect expression patterns. To counter these problems, bacterial
artificial chromosome (BAC) based transgenesis has gained in prominence. In BAC
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transgenesis, a large chunk of genomic DNA (usually greater than 100kb), containing the
gene of interest, is modified in Escherichia coli, such that the transgene follows the ATG
translation initiation site, rather than the coding sequence of the original gene. The whole
BAC is then used as a transgenic construct, so that the resulting progeny mice express the
transgene under the full set of promoter elements of the original gene (Yang et al., 1997;
Gong et al., 2002). This tends to produce transgene expression that much more closely
parallels the distribution of expression of the original marker gene, with less variation due
to positional effects.
Individual BAC transgenic mouse lines have been created that express fluorescent
proteins of different colors in a number of feeding-related neuronal subsets (Gong et al.,
2003). Because these mice allow easy identification of labeled neurons, they have been
essential for studies of co-localization, gene expression, electrophysiology, and plasticity
(Liu et al., 2003a; Pinto et al., 2004; Roseberry et al., 2004). In one study of mice
expressing different GFP variants under the control of the NPY and POMC promoters, it
was discovered that the numbers of inhibitory and excitatory axosomatic synaptic
connections and postsynaptic currents onto these ARC neuronal populations were
different between wild-type and ob/ob mice (Pinto et al., 2004). Most strikingly, these
differences were corrected by administration of leptin to ob/ob mice, an effect which was
observed as early as 6 hours post-treatment. While the source of the axosomatic contacts
and postsynaptic currents onto these cell populations remains unclear, this study clearly
revealed a new dimension to the complexity of the hypothalamic feeding circuit. At the
same time, it concretely demonstrated the profound utility of marker genes, and the
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marker gene-based transgenic approach, for the study of this, or any, system of neuronal
circuitry.
While most BAC transgenic mice created to date have been engineered to express
GFP variants or cre recombinase in neuronal populations of interest, there is no technical
limit to the variety of transgenes that might be used to investigate the biology of the
feeding circuitry.

Efforts are already underway to express modulators of neuronal

activity in specific cell types. Neuronal activity could be modulated by a number of
different transgenic strategies, for example by expressing ivermectin-sensitive chloride
channels to allow for temporospatial inhibition of neuronal activity (Slimko et al., 2002).
Forcible activation or inhibition of specific neuronal populations will be a critically
important strategy for determining the contribution of these populations to behavior, and
for investigating their impact on downstream neurons.
Undoubtedly, the study of NPY/AgRP and POMC/CART neurons has greatly
increased our understanding of the leptin-responsive feeding circuit and the regulation of
food intake and body weight. However, because of the vast array of significant data
regarding these ARC populations, it became customary to consider the ARC as the most
important first order leptin-responsive site within the hypothalamus. In fact, the data is
beginning to suggest that other nuclei that express the leptin receptor may play an equally
important role in sensing and responding to leptin. POMC-specific deletion of the leptin
receptor (POMC-cre X flox-ObR-flox mice) does result in hyperphagia and increased
adiposity, but the phenotype is only a small fraction of that observed for the db/db mouse
(Balthasar et al., 2004). Interestingly, knockout of the receptor in VMH neurons, using
an SF-1-cre transgenic line, leads to a similar adiposity phenotype (H. Dhillon, personal
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communication). These results have led to the emerging realization that all Ob-Rb
expressing hypothalamic nuclei likely play an important role in the response to leptin,
and thus are all of great importance to the overall task of energy homeostasis.
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Specific Aims

Traditional approaches to studying the hypothalamic control of feeding and body
weight revolved around lesioning experiments to identify nuclei of interest that
specifically contributed to feeding behavior. However, it has slowly come to light that
brain regions such as hypothalamic nuclei, though they may appear to be composed of
homogeneous populations of neurons, may in fact be extremely complex, not only in
structure, but in gene expression, connectivity and function. In the ARC, two opposing
populations of neurons, with differing gene expression, function, and connectivity, are
co-mingled with similar sub-nuclear patterns of localization. In addition to labeling these
populations, the genetic markers for these populations, NPY/AgRP and POMC/CART,
have been successfully used to drive transgene expression in these very subsets, allowing
for detailed experimentation and analysis. Thus, the definition of neuronal subtypes based
on the expression of marker gene expression rather than anatomic localization or
morphology is advantageous not only from the point of view of improved neuronal
discrimination, but also in the potential for targeted study. Indeed, the subpopulations in
the ARC have been so successfully analyzed that the ARC is now commonly regarded as
the primary site of leptin action in the hypothalamus. Recent evidence suggesting a
similarly important role for the VMH in the first-order response to leptin suggests a
critical role for this nucleus in leptin sensing. If this is the case, then full understanding
of the leptin response and hypothalamic energy homeostasis demands intensive study of
this nucleus in an analogous fashion to study of the ARC.
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However, while several lines of evidence have established that the VMH plays an
important role in controlling food intake, glucose metabolism and body weight, efforts to
determine how specific classes of VMH neurons mediate these processes have been
hampered by the lack of a set of marker genes that could facilitate a molecular analysis of
their function. To that end, this thesis aims to investigate gene expression in the VMH
with the aim of discovering genes that may be used as markers for its component
neurons. As nucleus-specific marker genes are most useful as drivers for transgene
expression, particularly for tracing experiments and studies of gene expression, we
endeavored to define VMH markers through microarray comparison of VMH RNA with
RNA from two adjacent nuclei, the ARC and DMH, isolated using laser-capture
microdissection.

The results of this intial screen, validation, and follow-up

experimentation on the VMH marker genes discovered are included.
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Chapter 2: Materials and Methods

Animal Care and Maintenance
All mice were either purchased from The Jackson Laboratory (Bar Harbor, ME) or bred
at Rockefeller University. Animals were housed at the Rockefeller Laboratory Animal
Research Center (LARC), subject to a 12 hour light:dark cycle (600-1800 hr light, 1800600 hr dark). All animals were cared for according to institutional guidelines.

Northern Blotting
Tissues were dissected from mice using sterile instruments, and total RNA was isolated
using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.
15µg of RNA from each sample were run on a 1% agarose, 1X MOPS, 18%
formaldehyde gel. After running, the gel was washed in DEPC-H20, washed for 15 min
in 0.05N NaOH, 2x 15 min in 10X SSC, and transferred in 10X SSC onto a Hybond-N+
membrane (Amersham, Buckinghamshire, UK). All solutions were made with DEPCH20. Each 32P-radiolabeled probe was generated by PCR, and the membrane was
hybridized with the probe at a concentration of 10^6 cpm/ml in Rapid-Hyb (Amersham,
Buckinghamshire, UK) overnight at 650C. The next day, the membrane was washed for
15 min at room temperature in 2x SSC/0.1% SDS, followed by washing for up to 2 hours
in 0.1X SSC/0.1% SDS at 650C. The membrane was exposed to BIOMAX MR x-ray
film (Fisher Scientific, Hampton, NH) at –800C for 1-7 days, and then developed. The
probes for LBH2, Cbln1, and PACAP were created using modified T3 and T7 primers
(modified T7 primer 5’-CGACTCACTATAGGGAATTTGGC-3’, modified T3 primer
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5’-CTAAAGGGAATAAGCTTGCGGCC-3’), using the original NMHY clone plasmids
as templates.

Southern Blotting
10µg of LBH2 BAC DNA was digested in with HindIII overnight at 370C, and then run
on a 1% agarose 1X TAE gel. After running, the gel was treated with denaturing solution
(1.5M NaCl, 0.5N NaOH) for 20 min, followed by 20 min treatment in neutralization
solution (1.5M NaCl, 1mM EDTA, 0.5M Tris pH 8.0), followed by a brief rinse in 10X
SSC.

The gel was then transferred to a Hybond-N+ membrane (Amersham,

Buckinghamshire, UK) in 10X SSC. Each 32P-radiolabeled probe was generated by
PCR, and the membrane was hybridized with the probe at a concentration of 106 cpm/ml
in Rapid-Hyb (Amersham, Buckinghamshire, UK) overnight at 65C. The next day, the
membrane was washed for 15 min at room temperature in 2x SSC, followed by washing
for up to 2 hours in 0.1X SSC at 650C. The membrane was exposed to BIOMAX MR xray film (Fisher Scientific, Hampton, NH) at –800C for 1-7 days, and then developed.

Quantitative Real-Time PCR
Quantitative real-time PCR was performed on RNA from microdissected hypothalamic
nuclei. First, roughly 2ng RNA from each sample were reverse transcribed with random
hexamers using Taqman Reverse Transcription Reagents (Applied Biosystems, Foster
City, CA) to produce cDNA. Real-time PCR was performed using Taqman Universal
PCR Master Mix (Applied Biosystems, Foster City, CA) on an ABI Prism 7700
Sequence Detection System (Applied Biosystems, Foster City, CA). Control RNA was
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prepared from whole hypothalamus using Trizol reagent (Invitrogen, Carlsbad, CA)
according to the instructions of the manufacturer. Data analysis was performed using
SDS 1.9.1 software (Applied Biosystems, Foster City, CA). The primer and probe sets
used are summarized in Table 1. Cyclophilin primers and probes were used as a control,
and each sample was normalized against cyclophilin data. Each sample was run in
duplicate, and the results are the average of three independent experiments.

Laser-Capture Microdissection
Tissue preparation and staining. 8 week old female C57Bl6/J mice were sacrificed, and
brains were manually dissected and frozen immediately in Tissue-Tek O.C.T 4583
(Sakura, Santa Rosa, CA). The frozen blocks were sectioned on a cryostat (Leica, St.
Gallen, Switzerland) to a thickness of 10 microns, and immediately adhered to plain,
uncharged slides (VWR, West Chester, PA). Sections on slides were fixed for 1 minute
in 100% EtOH, and then rehydrated with a graded alcohol series (95%, 75% 50%, 30 s
each) and stained for 1 minute in filtered 0.5% cresyl violet acetate (Sigma-Aldrich, St.
Louis, MO). Next, the sections were again dehydrated with EtOH (50% for 30 s, 75% for
30 s, 95% for 30 s, 100% for 1 min) and finally cleared with Histo-Clear (AGTC
Bioproducts, Beverley, UK) for 1 minute. Before microdissection, slides were allowed to
thoroughly dry, as the presence of water in the sections interferes with cap adhesion. All
solutions were made with autoclaved 0.1% DEPC water.
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Table 1 Sequences of Taqman Real-Time PCR Probe/Primer Sets
Gene

Forward Primer

Probe Sequence

Reverse Primer

PACAP
Guanine Deaminase
Cerebellin 1
Steroidogenic Factor 1
D123
Slit3
LBH2
P450 2J9
P450 2JX
ARP-1
Ten-m2
3-OST4
EST AA982708
Cyclophilin

5'-CTGCAGAAGCCAGCTCTGTTC-3'
5'-TGGAAAGCAGGTCGTTCCA -3'
5'-ACACAGGAAAGGCAAAGGGA -3'
5'-AGCTGCTGGTGTTGGACCA -3'
5'-GCAGCCCAGCCCCTATCT -3'
5'-GTGCAACGCCTGCCTCTC -3'
5'-TGCTCCAGTAACAGATGCGG -3'
5'-CTGCATGGGAGACACTGGTG -3'
5'-GAAAACGTGCTTGTCTTGGAGA -3'
5'-TGCAGATCACGGACCAGGT -3'
5'-AGACAGAATGAGATGGGAAAGAGG -3'
5'-CCTGAGGTTGGCAAAGATGAA -3'
5'-GCCTACATGATACCAGAAGGGTG -3'
5'-TGTGCCAGGGTGGTGACTT -3'

5'-GGAAGGAGGGTCTCCAGAAAATCCACAA -3'
5'-TCTCCAGCTCAGTGTAAGGACCTTGGACA -3'
5'-CCTGCTACGGGAGACAGCGCAGA -3'
5'-CGCCAGGTCCAGTACGGCAAGG -3'
5'-AGCTTCGGGCTGCCCAAGGACTT -3'
5'-AGCCCGTGCAAGAACAACGGCA -3'
5'-GGTGGTCAGAGAGTAGAGCCTGCCACA -3'
5'-CTCCCATTTGAGCCGGTAAAATTAAGGTGAC -3'
5'-TGATAAAAATGAACAGCTCAGACCTGGCCAG -3'
5'-GCCCTCCTTCGCCTCACCTGG -3'
5'-AACAAAATAACCTGCTGCCACCTCTTCTCTG -3'
5'-GCTTGTAACTGTGGGTATCAGGCAAACCC -3'
5'-TGCTCTACCAGCTCCACACATGCTTGA -3'
5'-ACACGCCATAATGGCACTGGTGG -3'

5'-AATGCATGAGGGCAAGGGT-3'
5'-TCCCAGGAGAATGTCGCAG -3'
5'-GCCTTCTTCGCAGAGCCAT -3'
5'-TCCAGTAACCAGCAGGATGCT -3'
5'-TCCCCGGTGGAAAGGTCTAC -3'
5'-CACGGGATCCTGACTGCAA -3'
5'-TCCTGGGATGGAGGTCCTCT -3'
5'-TCTTAGTCTCATTGCACGCACTC -3'
5'-GGGCTTGAAGGTAAATTTTTGGA -3'
5'-CGCATTCAACACGAACAGCT -3'
5'-GTTGCTCCTGCTGAGCCAC -3'
5'-GCCACCCACCAAGAGGCT -3'
5'-GCCAGCAGCCAAGACTTTAAA -3'
5'-TCAAATTTCTCTCCGTAGATGGACTT -3'

Microdissection. ARC, VMH, and DMH tissue were microdissected out of a series of 10
evenly spaced Nissl-stained sections covering the region from 1.46 mm to 1.94 mm
caudal to bregma as defined by The Mouse Brain in Stereotaxic Coordinates (Franklin
and Paxinos) using a Pixcell II Laser-Capture Microdissection System (Arcturus,
Mountain View, CA). Microdissection was performed using a beam-width of 15µm,
using maximum power and a beam duration of 100 ms. Each sample of collected tissue,
adherent to the underside of the LCM cap, was then dissolved in 50µl of digestion buffer
(Stratagene, La Jolla, CA) and frozen at –800C. Later, RNA was extracted from these
samples using the Absolutely RNA microprep kit (Stratagene, La Jolla, CA). The
digested tissue from all ten evenly spaced sections were pooled prior to RNA extraction
to eliminate any potential rostral-caudal gene expression bias in subsequent analysis.
Typical pools contained roughly 20 ng of RNA.

Microarrays
RNA Amplification and Hybridization. RNA collected from microdissected tissue was
amplified using the MessageAmp system (Ambion, Austin, TX). This system utilizes T7
polymerase to produce a linear amplification, with large quantities of antisense RNA as
product.

This aRNA was labeled with either Cy3 or Cye5 dyes via the following

protocol. For each sample, 8 µg of aRNA added to 10µg of random hexamers (Promega,
Madison, WI) in a total volume of 24µl in DEPC water. Samples were incubated at 700 C
for 10 min, chilled on ice and spun down. To each sample was added 10µl 1st strand
buffer for Superscript II (Invitrogen, Carlsbad, CA), 5µl of 0.1M DTT, 1µl of 25mM
d(AGC)TP, 2µl of 1mM dUTP-Cy3 or Cy5 (Amersham, Buckinghamshire, UK), 2µl of
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1mM dTTP, 2µl of Rnasin (Promega, Madison, WI), and 4µl Superscript II (Invitrogen,
Carlsbad, CA). The samples were incubated at room temperature for 10 min, followed
by incubation at 370C for 2 hours. Subsequently, the samples were treated with two units
of Rnase H (Promega, Madison, WI), for 20 min at 370C. The labeled cDNA was then
purified using the QiaQuick PCR purification kit (Qiagen, Los Angeles, CA) according to
the manufacturer’s instructions, with elution in two rounds totaling 80µl. The eluted
cDNA was then concentrated down to less than 20 µl using Microcon YM-10 columns
(Millipore, Billerica, MA), spun at 12,000g.

Microarray Hybridization. Labeled probes were hybridized onto cDNA arrays in a
Genetac cDNA Hybridization Station (Genomic Solutions, Ann Arbor, MI) according to
the manufacturer’s instructions. Two different cDNA arrays were probed. The first
contained 27,588 features comprised of Incyte, NCI, and Image Consortium clones with
4 bacterial genes as controls. The second array was made from a normalized mouse
hypothalamic cDNA library comprised of roughly 5000 clones, constructed by Dr.
Marcelo Soares. This library was the result of subtraction of a parent hypothalamic
library with a mouse total brain library to select for hypothalamic-enriched clones. Both
arrays were printed at the Albert Einstein College of Medicine microarray facility.
Following washing, slides were imaged using a Scanarray Lite scanner (GSI Lumonics,
Northville, MI) and ScanArray Express software (PerkinElmer, Wellesley, MA) at
532nm and 635nm. Thus, for each slide separate TIF files were produce for the Cy3 and
Cy5 signals.
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Data Analysis. Slide images were analyzed using GenePix 3.0 software (Molecular
Devices, Sunnyvale, CA). Results from each slide were normalized via an intensity
dependent normalization using a rank-invariant technique to select the normalization set
(Tseng et al., 2001; Yang et al., 2002). Results are averages of two separate sets of
experiments.

In Situ Hybridization Histochemistry
Tissue Preparation. Expression of candidate VMH marker genes was verified by in situ
hybridization histochemistry as previously described (Marcus et al., 2001; Liu et al.,
2003a), using 8 week old female C57Bl6/J mice. For studies of Cbln1 expression in SF-1
knockout mice, mice with a brain-specific KO of SF-1 were generated using a conditional
SF-1 allele and the nestin-Cre transgene (The Jackson Laboratory, Bar Harbor, ME) and
sections from the mediobasal hypothalamus were analyzed by in situ hybridization with
the Cbln1 probe described below.

Mice were anesthetized with 600 mg/kg

intraperitoneal (IP) chloral hydrate (Sigma-Aldrich, St. Louis, MO) and perfused
intracardially with 10% neutral buffered formalin solution (Sigma-Aldrich, St. Louis,
MO). Brains were dissected out and post-fixed for 4 hours in 10% formalin at RT.
Subsequently, the brains were dehydrated overnight at 40C with 30% sucrose in 1X PBS.
The brains were then sectioned to a thickness of 25µm using a cryostat (Leica, St. Gallen,
Switzerland). Sections were stored in antifreeze solution (5 parts 10% neutral buffered
formalin, 3 parts ethylene glycol, 2 parts glycerol) at –200C until needed, at which time
they were mounted on Superfrost slides (Fisher Scientific, Hampton, NH), dessicated and
frozen until use at –200C.
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Probe Manufacturing. Probes for ISHH were manufactured by cloning fragments of the
LBH2, Cbln1, and PACAP cDNAs amplified by PCR first into the pGEM-T vector
(Promega, Madison, WI), and then they were excised by EcoR1 digestion and cloned into
the EcoR1 site of pBluescript IIKS+ (Promega, Madison, WI). Depending on insertion,
plasmids were then cut with either Sal1 or Not1, and both sense and antisense 35S probes
were created by transcription with either T7 or T3 polymerases (Promega, Madison, WI)
according to the manufacturer’s protocol.

Hybridization. Slides were fixed in 4% paraformaldehyde in DEPC-treated 1X PBS at
40C for 20 min, dehydrated with a graded alcohol series (3 min each of 50%, 70%, and
95% EtOH, quick wash in 100% EtOH, and then 3 min in 100% EtOH), cleared with
xylene for 15 minutes, rehydrated with the reverse ethanol series, and placed in
prewarmed sodium citrate buffer (950C, pH 6.0), and microwaved in a commercial oven
(1100 watts) for 10 minutes at 70% power. The slides were then dehydrated with the
same alcohol series and air-dried. Probes were diluted to 106 cpm/ml in hybridization
solution (50% formamide, 10 mM Tris-Hcl pH 8.0, 5.0 mg tRNA (Roche Diagnostics,
Indianapolis, IN), 10mM DTT, 10% dextran sulfate, 0.3M NaCl, 1mM EDTA pH 8.0, 1X
Denhardt’s solution (Sigma-Aldrich, St. Louis, MO)).

Hybridization solution was

applied to the slides, and they were coverslipped and incubated overnight at 570C.
Subsequently, the coverslips were removed, and the slides were washed with 2X sodium
chloride/sodium citrate buffer pH7.0 and incubated with 0.002% RNAse A (Promega,
Madison, WI) in 0.5M NaCl, 10mM Tris-HCl pH 8.0, 1mM EDTA for 30 min. Sections
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were rinsed in SSC (2X for 1 hour at 500C, 0.2X for 1 hour at 55C, and 0.2X for 1 hour at
600C). They were then dehydrated with an ethanol series containing 0.3M NH4Oac
followed by 100% ethanol. The slides were air-dried and exposed to VMR-2 film
(Kodak, NY), for 2-3 days. Next, the films were developed, and the slides were dipped
in NTB2 photographic emulsion (Kodak, Rochester, NY), dried and stored in sealed
boxes for roughly 2 weeks.

Slides were developed with D-19 developer (Kodak,

Rochester, NY), counterstained with thionin, and coverslipped with Permaslip (Alban
Scientific, St. Louis, MO).

FACS-sorting of SF-1 Neurons
Mice bearing an eGFP transgene under the control of the SF-1 promoter (SF-1-eGFP)
were previously described (Stallings et al., 2002). These mice were bred onto WT, SF-1
+/- (Het), or SF-1 -/- (KO) backgrounds and males were sacrificed at E16.5. Brains were
dissected and trypsinized, and eGFP-positive neurons were resolved by FACS essentially
as described (Motoike et al., 2000).

RNA was isolated using Trizol (Invitrogen,

Carlsbad, CA), and was reverse transcribed using SuperScript III reverse transcriptase
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Real-time PCR
was performed on the cDNA as described above.

Expression of LBH2-EGFP fusions protein in 293T Cells
Cloning. A 1 kb fragment of the EGFP cDNA (lacking the ATG) was amplified by PCR
(forward primer 5’-CGGAATTCTCGTGAGCAAGGGCGAGGA-3’ with a 5’ EcoR1
site, reverse primer 5’-CCGCTCGAGCGATTTCGGCCTATTGG-3’ with a 5’ Xho1
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site), and ligated into the vector pcDNA3.1(+) following digestion with EcoR1 and Xho1
to produce the plasmid pcDNA.xEGFP. Next, a 700 bp fragment of the LBH2 cDNA,
containing 120 bp of 5’ untranslated sequence and lacking a stop codon, was amplified
by PCR (forward primer 5’-CGGGATCCGACCAGGGAGGCGAG-3’ with 5’ BamH1
site, reverse primer 5’-CGGAATTCCGAGAGTAGAGCCTGCCACA-3’ with 5’ EcoR1
site) and ligated into pcDNA.xEGFP following digestion with BamH1 and EcoR1,
producing the vector pcDNA.LBH2xEGFP. The resulting plasmid expresses a fusion
protein of LBH2 with EGFP, with the initiator methionine of EGFP replaced by a Gly-Ile
linker, under the control of the CMV promoter. The upstream region of LBH2, as well as
the LBH2 Kozak sequence and initiation codon are intact, in order to test their
effectiveness in vitro.

Cell Culture and Transfection. HEK-293T cells were cultured in Dulbecco’s Modified
Eagle’s Medium (Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum,
100 U/ml penicillin G, 100 µg/ml streptomycin sulfate, and 250 ng/ml amphotericin B
(Invitrogen, Carlsbad, CA) in a 370C incubator with 5% CO2. Cells were grown on 10
cm plates to 90% confluence and transfected with 20 µg of either pcDNA.LBH2xEGFP
or the control plasmid pcDNA.xEGFP using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA), according to the manufacturer’s instructions. Cells were imaged the following day
for EGFP fluorescence using an Axiovert 200 inverted fluorescence microscope (Zeiss,
Oberkochen, Germany), fitted with an LD A-Plan 40X objective (Zeiss, Oberkochen,
Germany).
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Generation of LBH2-GFP BAC Transgenic Mice
Creation of Shuttle Vector. The BAC RP24-94019, containing the LBH2 gene and
roughly 100kb both upstream and downstream, was purchased from the BACPAC
Resource Center of the Children’s Hospital Oakland Research Institute (Oakland, CA).
A ~450 bp fragment (LBH2 homology box) of genomic DNA directly 5’ to the ATG start
site

of

LBH2

was

amplified

by

PCR

(forward

primer

5’-

TTGGCGCGCCAGCCACCTGACTCAAACTTG-3’ including a 5’ Asc1 restriction site,
reverse primer 5’-GCTGTTGCTATTGCTACTGGGC-3’).

This PCR fragment was

digested with Asc1 enzyme and ligated into the shuttle vector pLD53.SCA-E-B, which
had been digested with Asc1 and Sma1.

BAC Modification. BAC modification was performed as previously described (Gong et
al.). E. coli harboring BAC RP24-94019 were grown in Luria broth (LB) (Invitrogen,
Carlsbad, CA), supplemented with chloramphenicol (20 µg/ml) to an OD600 of 0.6-0.8.
Cells were harvested by centrifugation at 3,000 x g for 10 min at 40C, and were
resuspended in 5ml of ice-cold 50mM CaCl2. Centrifugation and resuspension were
repeated. Finally, the cells were resuspended in 300 µl of 50mM CaCl2 plus 20%
glycerol, yielding BAC competent cells. 100 µl of competent cells were transformed
with 40 ng of the RecA expressing vector pSV1.RecA, and the cells were shaken at 300C
for 1 hr following addition of 1 ml of SOC medium (Invitrogen, Carlsbad, CA). 5 ml of
LB supplemented with 10 µg/ml tetracycline and 20 µg/ml chloramphenicol (SigmaAldrich, St. Louis, MO) was added, and the cells were incubated overnight in a 300C
shaker. The next day, 1 ml of overnight culture was added to 50 ml LB with 10 µg/ml
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tetracycline and 20 µg/ml chloramphenicol, and the cells were grown at 300C with
shaking to an OD600 of 0.6 – 0.8. Cells were harvested by centrifugation at 3000 rpm
for 10 min at 40C, and resuspended in 50 ml of cold 10% glycerol. This washing step
was repeated, and then finally the cells were spun down and resuspended in 200 µl of
10% cold glycerol. Next, these competent cells were transformed with the modified
shuttle vector. 1 µg of shuttle vector DNA was added to 40 µl of competent cells, and the
mixture was incubated on ice for 1 min. Next, the mixture was added to a 0.1 cm cuvette
(BIO-RAD, Hercules, CA) and electroporated with the following conditions: capacitance
25 µF, voltage 1.8 kV, resistance 200 Ohms. After electroporation, 1 ml of SOC medium
was added to the cells, and they were shaken in 15 ml tubes at 300C for 1 hr.
Transformed cells were selected by adding 5 ml of LB containing 10 µg/ml tetracycline,
20 µg/ml chloramphenicol, and 50 µg/ml ampicillin, with shaking overnight at 300C.
The following day, 100 µl of cells were spread onto LB agar plates containing 20 µg/ml
chloramphenicol and 50 µg/ml ampicillin, and the plates were incubated overnight at
430C. Genomic DNA for genotyping was procured using the Wizard SV Genomic DNA
Purification System (Promega, Madison, WI) according to the manufacturer’s
instructions.

Screening. Colonies from the above plates were screened to find clones which had
undergone the proper targeted recombination. Screening of BAC DNA was performed
by Southern blot as described above, using the original LBH2 homology box as a probe.
Original unmodified BAC was used as a control. Positive clones were those for which
the original band had been replaced by two new bands of different size.
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BAC Purification, Transgenesis, and Genotyping. The correctly modified BAC was
purified via the cesium chloride method and injected into FVB/NJ pronuclei by the staff
at GENSAT (Rockefeller University, NY). Founder mice, and subsequent progeny, were
screened by PCR (forward primer 5’-CCTACGGCGTGCAGTGCTTCAGC-3’, reverse
primer 5’-CGGCGAGCTGCACGCTGCGTCCTC-3’) for the presence of a ~500 bp
band.

Immunohistochemistry
Tissue Preparation. 6-10 week old mice were anesthetized with 600 mg/kg chloral
hydrate (Sigma-Aldrich, St. Louis, MO) IP and perfused intracardially with 4%
paraformaldehyde in 1X phophate-buffered saline (PBS). Brains were removed and postfixed overnight in 4% paraformaldehyde. For vibratome sectioning, the brains could
either be immediately sectioned after post-fixation, or could be stored indefinitely at 40C
in 1X PBS. For cryostat sectioning, brains were dehydrated following post-fixation by
immersion for two days in 30% sucrose in 1X PBS. Brains could be stored in 30%
sucrose/1X PBS for up to two weeks before sectioning.

Basic Immunostaining.

Free-floating 50 µm vibratome sections or 20 µm cryostat

sections of mouse brain, prepared as above, were washed 3 x 15 min in PBS, followed by
blocking for 1 hr at room temperature in blocking solution composed of 3% bovine serum
albumen (Cat# A9647, Sigma-Aldrich, St. Louis, MO), 2% goat serum (Cat# G9023,
Sigma-Aldrich, St. Louis, MO), and 0.1% Triton X-100. Next, sections were incubated
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overnight at 40C with primary antibody diluted in blocking solution. The following day,
the sections were washed 3 x 15 min in PBS, and then incubated at room temperature for
2 hours in blocking solution plus secondary antibody antibody (goat anti-mouse or goat
anti-rabbit antibody conjugated to either Alexa 488 or Alexa 594, Molecular Probes,
Eugene, OR) at a concentration of 1:1000. Subsequently, the sections were washed 3 x
15 min in PBS, mounted on 25mm x 75mm Superfrost/Plus slides (Fisher Scientific,
Hampton, NH), and coverslipped using Fluoromount-G (Southern Biotech, Birmingham,
AL). Primary antibodies used with this protocol include rabbit anti-GFP antibody (Cat#
A6455, Molecular Probes, Eugene, OR) diluted 1:1000, mouse monoclonal anti-GFP
antibody (Cat# MAB3580, Chemicon, Temecula, CA) diluted 1:1000, custom made
rabbit anti-LBH2 antibody (Washington Biotech, Columbia, MD) diluted 1:1000, and
mouse anti-NeuN antibody (Cat# MAB377, Chemicon, Temecula, CA) diluted 1:2000.

Anti-pSTAT3 Immunostaining. 8-10 week old mice were injected with 1 mg/kg leptin in
1x PBS 45 minutes prior to perfusion with 4% paraformaldehyde. Following overnight
post-fixation and cryoprotection with 30% sucrose in 1X PBS, 20 µm brain sections were
cut on a cryostat and washed in PBS for 15 minutes. The sections were then treated with
1% H202/1% NaOH in H20 for 20 minutes, 0.3% glycine for 10 min, and 0.03% SDS for
10 min, all at room temperature. Sections were then incubated at room temperature for
one hour with blocking solution, consisting of 3% goat serum, 0.25% Triton X-100, and
0.2% sodium azide in 1X PBS. Sections were then incubated for 48 hours at 40C with
rabbit anti-pSTAT3 antibody (Cat#9131S, Cell Signaling Technology, Cambridge, MA),
at a dilution of 1:3000 in blocking solution. Next, the sections were washed 3 x 15 min
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in PBS and incubated with biotinylated goat anti-rabbit secondary antibody (Cat# BA1000, Vector Laboratories, Burlingame, CA) diluted 1:1000 in the same blocking
solution for 1 hr at room temperature. The sections were then washed 3 x 15 min in PBS,
and treated for 30 minutes at room temperature with avidin-biotin-horseradish peroxidase
(ABC) complex (Vector Laboratories, Burlingame, CA). Sections were washed for 10
min in PBS, and then treated for 2-5 minutes with the peroxidase substrate DAB (Vector
Laboratories, Burlingame, CA).

The sections were mounted onto 25mm x 75mm

Superfrost/Plus slides (Fisher Scientific, Hampton, NH), and were left to air-dry
overnight. The following day, the slides were dehydrated with a graded ethanol series
(50%, 75%, 95%, and 100%, each for 2 min), followed by a 2 min immersion in citrus
clearing solvent (Richard Allan Scientific, Kalamazoo, MI).

Following a thorough

drying, the slides were coverslipped using Permount (Fisher Scientific, Hampton, NH).
When coupling this staining protocol with anti-GFP immunofluorescence staining, the
sections were washed in PBS following DAB staining, and then were transferred into the
basic immunostaining blocking solution and then stained exactly as described above.
Following fluorescent secondary antibody staining, the sections were mounted,
dehydrated and coverslipped with Permount as described in this section.

Anti-Estrogen Receptor-Alpha Immunostaining. 20 µm brain sections were cut on a
cryostat and washed 3 x 15 min in PBS. Sections were then blocked for 1 hr in blocking
solution consisting of 1% goat serum and 4% (yes, 4.0%) Triton X-100 in PBS. The
sections were then incubated with rabbit anti-estrogen receptor alpha antibody (Upstate,
Lake Placid, NY), diluted 1:20,000 in the same blocking solution, for 48 hrs at 40C.
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Next, the sections were washed 3 x 15 min in PBS, and then were incubated with goat
anti-rabbit Alexa 594-conjugated secondary antibody (Molecular Probes, Eugene, OR)
for 2 hrs at a dilution of 1:1000 in PBS supplemented with 1% goat serum. Following
washing for 3 x 15 min in PBS, the sections were mounted on 25mm x 75mm
Superfrost/Plus slides (Fisher Scientific, Hampton, NH), and coverslipped using
Fluoromount-G (Southern Biotech, Birmingham, AL). If this protocol was used for dual
immunofluorescence staining, the other primary antibody (such as mouse monoclonal
anti-GFP (1:1000 dilution, Chemicon, Temecula, CA), was added along with the antiER-alpha primary antibody, and an additional appropriate secondary antibody was used
along with the goat anti-rabbit 594 conjugate.

Pseudorabies Virus Ba2001TK+
Virus culture and preparation. PK15 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum, 100
U/ml penicillin G, 100 µg/ml streptomycin sulfate, and 250 ng/ml amphotericin B
(Invitrogen, Carlsbad, CA) in a 370C incubator with 5% CO2. Cells were grown on 10
cm plates to 90% confluence and infected with Ba2001TK+ at an MOI of 1:100. After
roughly two days, when cell lysis was nearly complete, the cells and medium were
collected and centrifuged for 2 min at 1000 x g. All but 2 ml of supernatant was
discarded, the pellet was resuspended, and the solution was subjected to two rounds of
freeze-thaw. Subsequently, 100 µl aliquots were dispensed into eppendorf tubes, and
these were frozen at –800C until use. Typical titers used were 1 x 108 pfu/ml.
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Stereotaxic injection of Ba2001TK+. 8-12 week old male AgRP-cre mice or C57Bl6/J
control mice were anesthetized with IP ketamine/xylazine (60µl of a 25mg/ml ketamine
and 25 mg/ml xylazine cocktail). They were then placed in a stereotaxic apparatus (Kopf
Instruments, Tujunga, CA), restrained by ear bars. An incision was made in the scalp,
and the fascia was removed by swabbing with 3% hydrogen peroxide, revealing the
major skull landmarks bregma and lambda. Using the stereotaxic apparatus, a small hole
was drilled in the skull, and a Hamilton syringe containing Ba2001TK+ was passed
through so that it would reach the coordinates 1.45 mm caudal to bregma, 0.25 mm
lateral to bregma, and 5.7 mm beneath the surface of the skull, the correct coordinates for
the ARC. 0.15 µl of virus was injected over a period of 15 minutes, and the needle was
left to rest for 5 minutes. Subsequently, the needle was removed slowly and the incision
was sutured. At or before first observance of symptoms (including irritability, lethargy
and weight loss), animals were perfused intracardially with 4% paraformaldehyde and
brains were processed for immunohistochemistry as described above.

Microscopy
In Situ Hybridization and Immunofluorescence Imaging. Slides were imaged on an
Axioplan 2 imaging microscope (Zeiss, Oberkochen, Germany) fitted with a PlanNeofluar 5x/0.15NA objective using either a Spot Insight QE color digital camera
(OpelCo, Dulles, VA) or an AxioCam MRm CCD camera (Zeiss, Oberkochen,
Germany). Images were collected using AxioVision 3.1 Zeiss software.

Confocal Imaging. Slides were imaged on an Inverted Zeiss Axiovert 200 confocal
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microscope using LSM 510 software (Zeiss, Oberkochen, Germany), fitted with a CApochromat 40x/1.2 NA water immersion objective (Zeiss, Oberkochen, Germany).
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Chapter 3: Results

Microdissection of Hypothalamic Nuclei
In order to isolate VMH-enriched transcripts, we conducted a gene expression
comparison of hypothalamic nuclei. Laser-capture microdissection (LCM) was used to
isolate tissue from hypothalamic nuclei.

In this technique, a cap covered with a

thermoplastic transfer film is laid over a slide on which is mounted dehydrated, stained,
cryostat-sectioned tissue. When cells of interest within the tissue are identified via
microscopy, a near-infrared laser is activated, focally bonding the tissue to the film.
When the cap is removed, the cells of interest remain bound to the transfer film on the
cap, while the remaining tissue stays on the slide. The cap can then be placed on an
eppendorf tube containing digestion buffer to extract nucleic acids from the dissected
tissue.

LCM allows for far greater precision and reproducibility than punch-out

approaches, making it well suited for applications that require extremely accurate
dissection of complex three-dimensional structures (Emmert-Buck et al., 1996;
Bonaventure et al., 2002). In this case, because the comparisons were to be between
closely adjacent nuclei, a very high premium was placed on accuracy.
LCM was used to isolate VMH, ARC, and DMH tissue from Nissl-stained
hypothalamic sections of 8-week-old female C57BL/6J mice. The dissected tissue and the
residual sections from a typical microdissection are shown (Fig. 6). We focused on the
dorsomedial VMH for two reasons. First, this area contains nearly all of the leptin
receptor in this nucleus, implicating this area in the response to leptin and in energy
homeostasis (Mercer et al., 1996). Second, it is also the most neuron-dense region of the
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Figure 6 Laser-Capture Microdissection of Hypothalamic Nuclei
(a - b) A Nissl-stained section of mouse hypothalamus before (a) and
after (b) sequential dissection of VMH, DMH, and ARC tissue. (c - e)
Images of dissected DMH (c), VMH (d), and ARC (e) tissue, which is
adherent to the cap. Scale bars, 500 µm.

VMH. Dissecting only this subset of the VMH minimized glial contamination, which was
found in some cases to dilute the contributions from VMH neurons. As sources of RNA
for comparison with the VMH, the ARC was chosen because several ARC-specific genes
have already been identified and because this region is adjacent to the VMH (Elmquist,
2001). We also analyzed the DMH, another mediobasal nucleus adjacent to the VMH
with similar neuron density also implicated in energy balance and other physiologic
processes (Bernardis and Goldman, 1976; Gallo, 1981). For each sample, 10 evenly
spaced sections were dissected and the collected nuclear tissue was pooled to minimize
anterior-posterior bias. RNA was collected from the tissue using a commercial kit. The
total mass of RNA in each pooled sample was approximately 20ng.

Amplification and Microarray Hybridization
To assay RNA integrity, a large sample of tissue was collected from a single slide,
in order to yield a large enough sample of RNA for analysis. When this RNA was run on
a 2100 BioAnalyzer (Agilent, Palo Alto, CA), 28S and 18S rRNA peaks were clearly
visible (Fig. 7a-b), indicating that the RNA isolated from LCM-dissected samples was
relatively intact.
RNA was amplified using a T7-based system. T7-based systems amplify RNA in a
linear manner, in contrast with the exponential amplification produced by PCR, allowing
for more accurate microarray results. Amplification was performed in two rounds, the
first round with a poly-T-T7 primer, and the second with random primers (Fig. 7c). This
amplification scheme produced antisense RNA products that were heavily 3’ weighted,
averaging 400-600 bp in length. However, this type of product is quite compatible with
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Figure 7 RNA Analysis, Amplification, and Microarray Hybridization
An oversized LCM-dissected RNA sample (a) and total hypothalamus RNA (b) were
compared on an Agilent 2100 Bioanalyzer. The LCM sample shows distinct 28S and
18S peaks, indicating relatively intact RNA with modest degradation. (c) Schematic
of the T7-based linear amplification scheme used to amplify RNA collected from LCM
samples (adapted from Ambion). LCM RNA was amplified in two independent rounds.
(d) Typical microarray hybridization result. A 28,000 gene M2 slide hybridized with
labeled amplified ARC (Cy3, green) and VMH (Cy5, red) probes.

cDNA microarrays, because cDNA libraries tend to have the same 3’ bias.
RNA products from each nucleus were labeled with either Cy3 or Cy5 dye and used
to probe each of two different cDNA microarrays. The first array (named M2) was a
collection of 28,000 cDNA clones comprising 20,000 unique genes (Fig. 7d). This array
was composed mostly of embryonic and total mouse cDNA clones. The second array
(NMHY) was composed of a set of 5000 cDNA clones from a normalized mouse
hypothalamic cDNA library, which was selected for hypothalamic enrichment by
subtraction against a library from total brain. The hypothalamic-specific array was used
in combination with the general mouse arrays in order to yield the best possible gene
coverage.
The labeled RNA from each of the three nuclei was compared in pairwise manner
against labeled RNA from each of the other two, using reverse-color hybridization as an
added control.

Microarray results for each of the comparisons are shown (Fig. 8).

Overall, it was evident that the vast majority of genes (>99%) are expressed at similar
levels among the three nuclei. Nonetheless, it was possible to identify individual gene
products that were enriched in specific nuclei. For example, in the arcuate nucleus, a
number of previously identified ARC-specific genes were revealed, including POMC,
NPY, and neurokinin B (Gee et al., 1983; Gehlert et al., 1987; Marksteiner et al., 1992).
This was a good first confirmation that the method was effective for identifying nucleusspecific genes. For each of the nuclei, the up-regulated genes were analyzed further with
respect to their relative levels of expression.
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Figure 8 Microarray Analysis of RNA from Hypothalamic Nuclei
Normalized ARC versus VMH (a), DMH versus VMH (b), and ARC
versus DMH (c) cDNA microarray results on log-log intensity-value
plots.

Patterns of Transcription in Hypothalamic Nuclei
A macroscopic analysis of these genes revealed interesting information with respect
to transcription in these nuclei. The data revealed a substantial overlap between the set of
genes with high ARC/DMH ratios and those with high ARC/VMH ratios (Fig 9a). This
was expected because many ARC-enriched genes have already been identified. This same
pattern was evident when analyzing the expression profile of the VMH-enriched genes,
insofar as genes with high VMH/ARC ratios were also enriched in the VMH versus the
DMH (i.e., they had high VMH/DMH ratios) (Fig. 9b) In contrast, there was very little
overlap between genes with high DMH/ARC ratios and those with high DMH/VMH
ratios (Fig. 9c). Together, this suggests that the ARC and VMH express a number of
nucleus-enriched genes relative to adjacent areas of the mediobasal hypothalamus. In
contrast, it was substantially more difficult to identify RNAs in DMH that were not
expressed in either the VMH or ARC. Thus, the VMH, like the ARC, should have its
own unique transcriptional network, whereas the DMH seems to share its transcriptional
profile with other adjacent nuclei.

VMH Marker Genes
The genes with increased signals in the VMH samples compared with both the
DMH and ARC were further analyzed to confirm that they were in fact VMH-enriched
marker genes. In these experiments, we were especially interested in genes that showed
the highest geometric mean of VMH/ARC and VMH/DMH ratios (i.e., a VMH score).
Table 2 lists the genes with a VMH score >4.0. The list, which is headed by the canonical
VMH marker gene SF-1, includes neuropeptides, ESTs, and several other genes. To
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Figure 9 Analysis of Marker Gene Expression in Hypothalamic Nuclei
Marker gene comparisons using intentisy-value plots. (a) Genes with the
highest VMH/ARC ratios (gray squares) also display high VMH/DMH
ratios (red circles). (b) Genes with highest ARC/DMH ratios (gray squares
also display high ARC/VMH ratios (red circles). (c) In contrast, only a
small number of genes with high DMH/ARC ratios (gray squares) display
high DMH/VMH ratios (red circles).

Table 2 - Top VMH-Enriched Genes
VMH marker candidates are listed by VMH score (geometric mean of VMH/ARC and VMH/DMH ratio). Common names and
accession numbers are given, as well as the arrays on which the genes were found (28,000 gene total mouse and embryonic clone
array, 5,000 gene subtracted hypothalamus array, or both).
Gene Name
Steroidogenic factor 1
Mouse homolog of Rattus norvegicus D123 gene product
Mus musculus cytochrome P450 CYP2J9 mRNA
Mus musculus cerebellin 1 (Cbln1) precursor protein
Slit homolog 3 protein precursor (Slit3)
Pituitary Adenylate Cyclase Activating Polypeptide (PACAP)
Mus musculus similar to limb-bud and heart (LBH2)
Guanine deaminase
Heparan sulfate 3-O-sulfotransferase 4
EST - no significant homology
Mus musculus mRNA for Ten-m2
Apolipoprotein AI regulatory protein-1 (ARP-1)

Accession
Number
S65878
BC024787
AF336850
BC055730
AF144629
AB010149
XM_354697
AF174583
AA030506
AA982708
AB025411
X76653

Array
28k
28k
Hyp
Both
28k
Both
Hyp
28k
28k
Hyp
28k
28k

VMH/ARC VMH/DMH VMH
ratio
ratio Score
7.92
15.66 11.14
7.00
16.18 10.64
16.41
5.75
9.71
12.25
7.40
9.52
7.07
11.91
9.18
11.24
7.01
8.88
6.62
9.50
7.93
5.59
7.835
6.62
5.75
6.02
5.88
5.79
5.37
5.58
5.65
3.78
4.62
3.42
5.52
4.34

validate these microarray data, real-time PCR was performed for each of the top 12 VMH
candidate genes on independent samples of RNA collected from the ARC, VMH, and
DMH using LCM. These data confirmed the microarray results for 9 of these 12 genes:
SF-1, PACAP, Cbln1, EST XM_354697, Slit3, guanine deaminase, TenM2, 3-O-sulfotransferase 4 (3-OST-4), and EST AA982708 (Fig. 10). Three of the nine VMH marker
candidates were present exclusively on the 5000 gene hypothalamus-enriched array,
highlighting the utility of this library and suggesting that some VMH genes are not
expressed or are expressed at low levels elsewhere in the brain.
Although the real-time PCR data were consistent with the original microarray
results for these nine genes, thus validating the screening approach, the data for
cytochrome P450 CYP2J9, D123, and ARP-1 did not recapitulate the array results. The
basis for the apparent discrepancy for these three genes may be a result of crosshybridization of RNAs with cDNA probes for other genes with sequence similarity.
However, the consistency of the microarray results, especially with respect to cytochrome
P450 CYP2J9, suggests the presence of real VMH-enriched transcripts. The cytochrome
P450 family in particular is very large, with a number of genes with high degrees of
sequence homology. Real-time PCR was performed on ARC, VMH, and DMH RNA
using probes to unique and shared regions of CYP2J9 and closely related family
members, but the family member responsible for the VMH-specific signal could not be
isolated (data not shown).
Because the VMH is integrally involved in the regulation of food intake, and
because other hypothalamic nuclei express genes that are regulated at the level of
expression in response to changes in fed state, the validated VMH marker genes were
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Figure 10 Confirmation of Microarray Results by Real-Time PCR
Twelve VMH candidate markers (PACAP, Cbln1, EST/LBH2, Slit3, guanine deaminase,
TenM2, 3-OST-4, EST 982708, SF-1, ARP-1, D123, and cytochrome P450 CYP2J9) were
tested by real-time PCR analysis using RNA from microdissected ARC (A), VMH (V), and
DMH (D) tissue. For each gene, expression was normalized to cyclophilin, and results
from different nuclei were then normalized to the VMH, with VMH expression set at
100. Values are expressed as mean +/- SEM. Statistical significance, *p< 0.05.

analyzed for modulation of gene expression in response to fasting. Whole hypothalamus
RNA was isolated from 8 week old female mice which were either fasted for 24 hours or
fed ad libitum, and the expression of the VMH markers was analyzed in these RNA
samples. None of the genes showed differential expression in response to fasting (Fig.
11).

Validation by In Situ Hybridization
For the reasons stated above, the original dissection focused on the dorsomedial
VMH, raising the possibility that these cDNAs might be localized in this region of the
VMH. To further ensure that this screening system indeed produced legitimate VMH
markers and to establish their distribution within the VMH, we endeavored to determine
the general, and more specifically the hypothalamic, distribution of three of the genes:
PACAP, Cbln1, and the hypothalamic array EST XM_354697 (discussed in detail
below).
Cbln1 was initially isolated from rat cerebellum as a 16 aa peptide, and is derived
from what was originally believed to be a precursor molecule, precerebellin (Umrath and
Silberbauer, 1967; Urade et al., 1991). However, there are similarities between this
precursor and circulating complement C1q (Urade et al., 1991).

Additionally, the

precursor molecules of Cbln1 and its family members have been shown to multimerize,
indicating that the originally isolated 16 aa peptide may be a cleavage product of a larger,
functional molecule (Pang et al., 2000). Cbln1 is known to be expressed in Purkinje cells
of the cerebellum and cartwheel cells in the dorsal cochlear nucleus (Slemmon et al.,
1984; Mugnaini and Morgan, 1987). Previously, Cbln1 was shown to be expressed at
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Figure 11 Expression of VMH Marker Genes in Fed and Fasted Mouse Hypothalamus
Real-time PCR performed on total RNA from hypothalami of mice fed ad libitum (blue)
or fasted for 24 hrs (green). Genes tested were LBH2, Cbln1, PACAP, Slit3, EST
AA982708, TenM2, SF-1, Guanine Deaminase, and 3-OST4. For each sample, the
resulting value was normalized against cyclophilin. Values for fed animals were set
at 100. Values are expressed as mean +/- SEM.

high levels in the cerebellum and hypothalamus by whole tissue radioimmunoassay
(Morgan et al., 1988), but the details of its localization within the hypothalamus and most
other brain regions have not been described. Tissue panel northern blot revealed that
Cbln1 is expressed in the hypothalamus and cerebellin, and at lesser levels in other areas
of the brain, but expression was not observed in any of the peripheral organs tested (Fig.
12a).
PACAP is a neuropeptide which comes in 27 aa and 38 aa forms, cleaved from a
larger precursor protein, proPacap (Miyata et al., 1989). The CNS distribution of PACAP
has previously been reported. In the brain, PACAP is expressed in a number of brain
regions, including the hippocampus, the purkinje cell layer of the cerebellum, a number
of brainstem nuclei, and in the hypothalamus, prominently in the VMH (Hannibal, 2002).
By northern blot, PACAP is expressed strongly in the hypothalamus and to a lesser extent
in other brain regions (Fig. 12b).

PACAP signal was not observed in any of the

peripheral tissues tested.
The EST from the hypothalamic library was listed in GenBank under the accession
number XM_354697 and the name "similar to limb-bud and heart." Its characteristics are
described in greater detail below. By northern blot, this gene is expressed most strongly
in the hypothalamus, and to a lesser extent in the remainder of the CNS (Fig. 12c). Of
the peripheral tissues tested, the expression of this gene was detected (albeit at low level)
only in the spleen.
These three genes were analyzed by in situ hybridization, confirming that, within
the hypothalamus, they are all highly enriched in the VMH, with very low expression in
other areas of the hypothalamus, including the ARC and DMH (Fig. 13). Within the
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Figure 12 Northern Blot Analysis of
LBH2, Cbln1, and PACAP
Tissue panel Northern blots for Cbln1 (a),
PACAP (b), and EST XM_354697/LBH2
(c). Ethidium bromide staining of 28S
and 18S ribosomal bands is shown as a
loading control. Cer, Cerebellum; Hyp,
hypothalamus; WAT, white adipose
tissue.
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Figure 13 Comparison of PACAP, Cbln1, and LBH2 mRNA Distributions in the VMH
In situ hybridization images of PACAP (left), Cbln1 (middle), and LBH2 (right) expression in
the mouse VMH. Images are organized from rostral (top) to caudal (bottom). PACAP and Cbln1
are expressed in all subcompartments of the VMH, including the dmVMH, intVMH, and vlVMH.
LBH2 expression is restricted to the dmVMH and intMVH, and is not expressed in the vlVMH.
Scale bars, 200 µm.

VMH, there are distinct differences in their localization. While PACAP and Cbln1 are
expressed at high levels in all subdivisions of the VMH (dorsomedial (dmVMH),
intermediate (intVMH), and ventrolateral (vmVMH)), EST XM_354697 appears to be
expressed exclusively in the dmVMH and intVMH. Even in the most caudal sections,
when VMH neurons are predominantly laterally located, EST XM_354697 mRNA was
observed only in the intVMH.

Distribution of Cbln1 in the Mouse Brain
While the distribution of PACAP in the rodent brain has been previously reported
(Hannibal, 2002), no such study of the brain distribution of Cbln1 has been performed.
Cbln1 was expressed widely throughout the CNS (Fig. 14). Most notably, in addition to
expression in the VMH and cerebellum, strong Cbln1 hybridization was observed in the
lateral orbital cortex, dorsal endopiriform nucleus, ventromedial preoptic nucleus,
thalamic stria medullaris, triangular septal nucleus, a wide array of thalamic nuclei, the
latero-anterior and periventricular hypothalamic nuclei, ventral tegmental area, ventral
cochlear nucleus, and parviceullular part of the medial vestibular nucleus.

SF-1 Transcriptional Network
The identification of the SF-1 gene in this screen, along with a list of genes that
share its hypothalamic localization, suggested that this transcription factor might regulate
some of the other VMH-enriched markers. As discussed, SF-1 is a transcription factor
first identified based on its ability to bind to a common upstream region shared by a
group of cytochrome P450 steroid hydroxylases in the adrenal cortex (Lala et al., 1992).
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Figure 14 Distribution of Cbln1 mRNA in the Mouse Brain
Distribution of Cbln1 mRNA in mouse brain as determined
by in situ hybridization. Strong Cbln1 hybridization was
observed in the lateral orbital cortex (LO) and dorsal
endopiriform nucleus (DEn) (a), ventromedial preoptic
nucleus (VMPO) (b), thalamic stria medullaris (SM) and
triangular septal nucleus (TS) (c), antero-ventral (AV) and
anteromedial (AM) thalamic nucleus (d), latero-anterior
(LA) and periventricular (Pe) hypothalamic nuclei (e), zona
incerta (ZI) and ventromedial hypothalamic nucleus (VMH)
(f), paracentral (PC), oval paracentral (OPC), mediodorsal
(MD), para-ventricular (PV), centrolateral (CL), and
centromedial (CM) thalamic nuclei (g), ventral tegmental
area (h), ventral cochlear nucleus (VC) and cerebellum (Cer)
(i), and parvicellular medial vestibular nucleus (MVePC) (j).
Scale bars, 200 µm.

In SF-1 knock-out mice, there is a diffuse, disorganized collection of poorly developed
VMH neurons outside their normal anatomic position, as determined by the Parker group
using an SF-1-eGFP transgene (Fig. 15) (Davis et al., 2004). As a result of the abnormal
development of this nucleus, these mice develop late-onset obesity despite normal food
intake (Majdic et al., 2002).
Thus, as a first effort to define a genetic network that might mediate VMH-enriched
expression, we analyzed the expression of the confirmed VMH-enriched transcripts in
SF-1 knockout mice. Genes that are dysregulated in SF-1 neurons would represent
potential SF-1 target genes that might play a role in the proper development of this
nucleus. Using a previously described SF-1-eGFP transgenic line, we FACS sorted SF-1
neurons from WT and SF-1 knock-out and SF-1 heterozygous mice, as reported
previously (Stallings et al., 2002). Real-time PCR for each of the bona fide VMH marker
genes was then performed on RNA from these sorted neurons. The RNA levels for four
of the eight genes (Cbln1, Slit3, TenM2, and EST AA982708) were found to be markedly
reduced in samples from SF-1-/- mutant neurons versus wild-type or heterozygote
neurons (Fig. 16). In contrast, PACAP and guanine deaminase seemed to be induced in
the GFP-labeled neurons from the mutant animals, perhaps revealing a lack of feedback
signaling.
To confirm this result, we performed ISHH for Cbln1 on brain sections from wildtype and brain-specific SF-1 knock-out mice (Fig. 17). In sections from KO mice, the
SF-1 neurons expressed significantly less Cbln1 mRNA compared with sections from
wild-type animals. The signal intensity for Cbln1 was unaffected in the neighboring zona
incerta.
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Figure 15 Disordered VMH Neurons in the SF-1 Knockout Mouse
eGFP immunohistochemistry of hypothalamic sections of SF-1-eGFP mice
bred onto WT (a, c, e) or SF-1 knockout background (b, d, f). The box
indicates the area containing the VMH in WT animals. Adapted from
Davis et al. 2003.
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Figure 16 Expression of VMH Marker Genes in SF-1 Knockout Mice
Real-time PCR results for VMH marker genes on RNA from FACS-sorted
SF-1-eGFP neurons on WT, SF-1 heterozygote (Het), and SF-1 knockout
background (KO). All data points are normalized to cyclophilin, with WT
values set at 100. Values are expressed as mean +/- SEM. Statistical
significance, *p< 0.05.
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Figure 17 Cerebellin 1 Expression in WT and SF-1 KO Hypothalamus
Darkfield images (5x) of hypothalamic sections of WT control mice (a) and
brain-specific SF-1 KO mice (b) hybridized with a Cbln1 antisense probe.
Scale bars represent 1 mm.

Analysis of VMH Morphology in Slit3 Knockout mice
Of the candidate VMH marker SF-1 target genes, the most striking from the point
of view of neuronal organization and migration was the gene Slit3. The Slit proteins
(Slit1, Slit2, and Slit3) are secreted proteins, which bind to Robo family receptors. There
is abundant data that Slit proteins are integrally involved in neuronal migration and axon
guidance (Zinn and Sun, 1999). For instance, Slit1 repels neuronal precursors migrating
from the anterior subventricular zone in the telencephalon to the olfactory bulb (Wu et
al., 1999), while Slit2 has a chemorepulsive effect on cerebral cortical neurons and
olfactory interneuron precursors (Hu, 1999). While there is no data concerning the
activity of Slit3 in these processes, targeted deletion of Slit3 produces congenital
diaphragmatic hernia, kidney agenesis and cardiac defects, indicating significant activity
in tissue morphogenesis (Liu et al., 2003b).
Because of its tissue localization, regulation by SF-1, and suspected involvement in
neuronal modulation, we examined Slit3 knockout mice for evidence of similar VMH
irregularities as those observed in SF-1 knockout mice. However, immunostaining with
an antibody against the pan-neuronal marker NeuN revealed identical distributions of
VMH neurons in both Slit3 -/- and wild-type control mice (Fig. 18). As a follow-up, we
examined the distribution of estrogen receptor-alpha (ER-alpha) in these mice. The ERalpha neuronal distribution is profoundly affected by the loss of SF-1, as this group of
neurons, which normally occupies the extreme vlVMH, is found near the 3rd ventricle in
SF-1 knockout mice (Dellovade et al., 2000). However, the distribution of ER-alpha was
unaffected by deletion of Slit3 (Fig. 19).
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Figure 18 Distribution of VMH neurons in Slit3 Knockout Mice
VMH neurons are visualized by fluorescence immunostaining with an antibody against
NeuN, a pan-neuronal marker in wild-type (a) and Slit3 -/- (b) hypothalamus.
Scale bars, 200 µm.
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Figure 19 Hypothalamic ER-alpha Distribution in WT and Slit3 Knockout Mice
Fluorescence immunohistochemistry performed on hypothalamic sections from
WT (a) and Slit3-/- (b) mouse brains using an antibody against estrogen receptor-alpha.
Scale bars, 200µm.

LBH2
The VMH-enriched EST XM_354697 had not been characterized previously. This
gene was present in multiple copies on the hypothalamus-enriched array, but was not a
constituent of the 28,000 gene library. The transcript of this gene is roughly 800 bp, as
determined by northern blot (Fig. 12c).
The corresponding gene is composed of 4 exons, occupying 5.3 kb of the “+”
strand of chromosome 12 (qF1). The predicted product of this transcript is a 114 aa
protein, which shares a 29 aa stretch of 86% identity with limb bud and heart (LBH), a
putative transcription factor thought to play a role in limb and heart development (Briegel
and Joyner, 2001). Thus, based on the guidelines of the International Committee on
Standardized Genetic Nomenclature for Mice, we have named this gene LBH2. A
comparison of the protein sequences of LBH2 with LBH and the homologous proteins
"rat similar to XLCL2 protein" and "EST human LOC350101 protein" shows that this
gene is evolutionarily conserved, especially within a middle stretch of 50 aa (Fig. 20). An
LBH2-eGFP fusion protein expressed in 293T cells under the control of the
cytomegalovirus promoter showed that the native Kozak sequence and ATG were indeed
functional, and the distribution of the fusion protein within the cells was cytoplasmic
(Fig. 21).
Within the brain, LBH2 expression is mainly limited to only a few areas, as
determined by in situ hybridization. Specifically, LBH2 is expressed in the lateral septal
nucleus, the amygdala, and the VMH (Fig. 22). Low-level expression was also observed
in the exteral cortex of the inferior colliculus. As discussed previously, LBH2 expression
in the VMH is almost totally restricted to the dmVMH and intVMH, with almost no

87

20

E
K
K
E

40

G
G
T
M

S
T

Q
E

S
V

S
M

E
M

- WS
- N -

T
-

G
-

D
-

V
-

M
-

G
-

S
-

G
-

T
-

E
-

D
-

protein
protein
protein
protein

M
MG G E E G E
M
MS V Y

S
R
P
F

T
G
P
P

P
S
R
I

Q
Q
A
H

P
N
C
C

A
S
V
S

A
G
P
D

P
G
G
Y

E
M
A
L

S
Q
V
R

P
E
P
S

T
R
S
A

XM_354697/LBH2
Rat sim. to XLCL2
Human LOC350101
Mouse LBH

protein
protein
protein
protein

P
P
P
P

D

P

S

D

F

D

WL
R L
R L
R C

C
C
G
C

K

L

K

Q
Q
Q
D

R
R
R
R

L
L
L
L

P
P
P
P

S
S
S
S

I
I
I
I

V
V
V
V

E
E
E
E

P
P
P
P

T
T
S
T

E
E
E
E

A G A V E
A G A V E
A D P V E
G
E V E

S
S
S
S

G
G
G
G

E
E
E
E

L
L
L
L

R
R
R
R

WP
WP
WP
WP

P
P
L
P

E
E
E
E

XM_354697/LBH2
Rat sim. to XLCL2
Human LOC350101
Mouse LBH

protein
protein
protein
protein

P
R
-

A
S
-

A
F
-

R
-

A
-

P
-

G
-

I
-

S
-

G
-

C
-

T
-

P
P
P
-

G
G
P
K

K
K
A
K

E
E
D
D

A D D D V I Q G A S S G H Q A F P A P V T D A G V A G S T L
A D D D V I E G A S S G H Q A F P G P V T D K G V A G S A L
Q H G R L Y V S A A P S P S L P G E P G K A A D N A G S E C A C S E D P A A P A R G
Q

80

V
V
V
V
140

L
-

S
A

60

XM_354697/LBH2
Rat sim. to XLCL2
Human LOC350101
Mouse LBH

- WD
- P S

L
M

- P
L P
WD
E E

R
G
P
I

G
G
A
G

P
A
A
L

A
H
L
S

G
H
G
P

K
R
V
R

A
A
A
K

A
A
V
D

V
V
A
G

G
G
G
L

V
V
A
S

R E
R E
WE
Y Q

K
K
K
I

T
T
A
F

R
R
R
V

G
G
G
Q

P
-

T
T
P
-

P
P
S
E

Q
Q
Q
D

I
V
S
E

Q
Q
R
Q

A
A
A
D

A
A
A
N

A
A
A
C

A
A
A
E

P
P
Q
E

S
S
L
T

S
S
A
N

100

G
G
S
E

G
G
G
F
120

Q
Q
Q
L

T
-

P
P
P
T

P
P
K
E

160

Figure 20 LBH2 Family Protein Sequence Comparisons
Protein sequence alignments of LBH2, rat similar to XLCL2, Human LOC350101, and
mouse LBH. Light gray boxes indicate similarity, while dark gray boxes indicate identity.
All proteins share a high degree of identity between amino acids 76-104.
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Figure 21 Expression of LBH2-eGFP Fusion Protein in Cell-Culture
Fluorescence images of HEK 293T cells transfected with pcDNA-xEGFP (a) or
pcDNA-LBH2-xEGFP (b). Bright green fluorescence resulting from
pcDNA-LBH2-xEGFP transfection indicates that the predicted ATG and Kozak
sequences of LBH2 are functional.
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Figure 22 Distribution of LBH2 mRNA in the Mouse Brain
Distribution of LBH2 mRNA in the mouse brain as determined by in situ hybridization.
Strong hybrization signal was observed in the lateral septal nucleus (LSN) (a),
ventromedial hypothalamic nucleus (VMH) (b), posteroventral (MePV) and posterodorsal
(MePD) medial amygdaloid nuclei, posteromedial cortical amygdaloid nucleus (PMCo),
and anterolateral amygdalohippocampal area (AHiAL) (c), and the external cortex of the
inferior colliculus (ECIC) (d). Scale bars, 200 µm.

expression in the vlVMH.

LBH2 Antiserum
In order to analyze the distribution of LBH2 within the VMH in detail, rabbit antiLBH2 antiserum was created by injection of the peptide N-STPQPAAPESPTEGPRG-C
(representing amino acids 2-18 of LBH2) into rabbits. Antisera were affinity purified.
The resulting antisera was capable of labeling LBH2 neurons by immunohistochemistry,
illuminating the expression of this gene in much greater detail. The expression pattern of
LBH2 in the VMH and other brain regions as measured by immunohistochemistry
recapitulated the in situ hybridization results (discussed below). Additionally, confocal
imaging of LBH2 neurons in the VMH confirmed the predicted cytoplasmic localization
of the protein product of this gene (Fig. 23).

LBH2-GFP BAC Transgenic Mice
In order to learn more about VMH subpopulations, we endeavored to create
transgenic mice that expressed GFP under the control of the LBH2 promoter. A BAC
transgenic approach was taken, as this method allows for expression of a given transgene
under the full set of promoter elements of a gene of interest, whether they be proximal or
distal to the transcriptional start site. A 185 kb BAC (RP24-90O19), with roughly 130 kb
up upstream DNA and 40 kb of downstream DNA, was modified such that an EGFPpolyA construct was placed immediately following the native ATG site (Fig. 24). This
construct was injected into strain FVB/NJ pronuclei, resulting in the production of 45
founder mice. Of these founders, one had focal expression of GFP in the VMH, and

91

Figure 23 Cytoplasmic Localization of LBH2 Protein in VMH Neurons
Confocal fluorescence image of the dmVMH of wild-type hypothalamic
brain section immunostained with an antibody raised against LBH2 peptide.
The observed halo staining pattern is indicative of cytoplasmic expression.
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Fig 24 LBH2-eGFP BAC Modification
(a) Schematic of modification of LBH2-containing BAC RP24-90O19. Shown is
the original BAC, shuttle vector containing the homology box A and the eGFP-poly A
construct, AMP resistance cassette and R6Kgamma origin of replication.Homologous
recombination within the "A box" produces the modified BAC (bottom). (b) Southern
blot of HindIII digest of original BAC and 8 potential modified BAC clones, probed
with 32P-labeled A box. Modified clones 1-7 were successful, and clone #1 was
injected into FVB/NJ pronuclei.

produced pups with the expected Mendelian ratio. This mouse line was thus designated
LBH2-GFP.
Analysis of the LBH2-GFP mouse, by anti-GFP immunofluorescence, revealed
the expression of the transgene in a number of brain areas, in good agreement with the in
situ hybridization results. Specifically, LBH2-GFP mice express GFP in the lateral septal
nucleus, the VMH, the amygdala, and the piriform cortex (Fig. 25). Of these sites, all are
consistent with the expression profile revealed by in situ hybridization and
immunohistochemistry, except for the piriform cortex expression.
Bright GFP fluorescence in neurons of GFP transgenic mice is an essential
prerequisite to a number of different types of studies, including those involving cell
sorting and electrophysiology. To analyze the GFP expression of the LBH2-GFP mice,
fresh unstained sections were imaged by fluorescence microscopy. Native un-amplified
GFP fluorescence was clearly visible (Fig. 26).
While the LBH2-GFP transgene was clearly expressed in the correct areas of the
brain, it was still unclear whether the correct neurons in those areas were labeled. To
verify the expression of the transgene, dual immunofluorescence was performed, using
anti-GFP and anti-LBH2 antibodies.

Confocal microscopy was used, because

visualization of thin optical sections allowed for the most accurate possible investigation
of gene expression in discrete neurons. Within the VMH, there was excellent overlap of
anti-GFP signal with anti-LBH2 staining (Fig. 27 top). In general, all VMH neurons that
were positive for GFP were also found to stain positive with the anti-LBH2 antibody.
However, there appeared to be a low rate of observance of LBH2-expressing neurons that
could not be positively visualized by GFP. However, GFP could still be expressed in
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Figure 25 Hypothalamic eGFP Expression in LBH2-eGFP Transgenic Mice
Anti-GFP fluorescence immunostaining of brain sections from LBH2-GFP BAC
transgenic mice. Expression can be observed in the piriform cortex and amygdala (a),
lateral septal nucleus (b), and VMH (c-f). (d) In rostral VMH sections, eGFP
is expressed predominantly in the dorsomedial division of the VMH. (e) In middle
VMH sections, eGFP is expressed in all division of the VMH, most prominently in the
intermediate VMH. (f) In caudal VMH sections, eGFP is expressed almost exclusively
within the intermediate VMH. Scale bars, 400 µm (a-c), 200 µm (d-f).
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Figure 26 Natural eGFP Fluorescence in LBH2-eGFP Mice
Natural unstained fluorescence in the rostral VMH (a) and caudal VMH (b) in LBH2-eGFP
BAC transgenic mice. Scale bars, 200 µm.
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Figure 27 Validation of LBH2-eGFP BAC Transgenic Mice
Dual-fluorescence confocal images of LBH2-eGFP mouse brain sections
immunostained with both anti-LBH2 (red) and anti-GFP (green) antibodies.
Red (left), green (center), and merged (right) images are shown for staining of
the VMH (top), lateral septal nucleus (middle) and piriform cortex (bottom).

these neurons, albeit at low, undetectable levels. In the dorsomedial VMH, almost all
LBH2-expressing neurons were observed to be clearly labeled with GFP, at a rate
approaching 90%. This rate was equally high for LBH2-expressing neurons in the
intermediate VMH, but was slightly lower (roughly 80%), in the furthest lateral LBH2expressing neurons.
In the lateral septal nucleus, overlap between LBH2-eGFP and anti-LBH2
immunostaining was also quite good (Fig. 27 middle). Roughly 90% of LBH2 neurons
expressed the LBH2 transgene. However, in this nucleus, rare neurons could be found
that expressed eGFP but did not stain positive for LBH2. It is possible that the LBH2
antibody (which is quite weak) was not able to visualize legitimate expression in these
neurons, but that is not certain. In contrast, in the piriform cortcx, the situation was quite
different. As expected from the in situ hybridization data, there was no LBH2 expression
in this area as determined by anti-LBH2 immunohistochemistry (Fig. 27 bottom). Thus,
the eGFP expression in this compartment is an artifact. However, this erroneous piriform
cortex eGFP expression does not mitigate the utility of this transgene for the study of the
VMH. Especially weak staining with the anti-LBH2 antibody in the amygdala precluded
an assessment of trasngene expression in this nucleus. It is not susprising that this was
so, considering the relatively weaker expression of LBH2 measured by in situ
hybridization and the atypically weak expression of the LBH2-eGFP transgene in this
region.
All in all, LBH2 appeared to be expressed in the vast majority of dmVMH and
intVMH neurons.

Expression in the ventrolateral segment of the VMH was less

prominent, as expected. Next, we attempted to determine what proportion of VMH
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neurons in different VMH subcompartments expressed LBH2. To do so, we performed
dual label immunohistochemistry on LBH2-GFP mice using the anti-GFP antibody and
an antibody against the pan-neuronal marker, NeuN (Fig. 28).

Analysis of stained

sections by confocal microscopy revealed that LBH2-expressing neurons accounted for
roughly 80% of all neurons in the dorsomedial division of the hypothalamus. LBH2
neurons were found less frequently in the intermediate division of the VMH (roughly
80%), and even less in the lateral section of the VMH (<5%).
We also co-stained LBH2-GFP sections with a rabbit anti-SF-1 antibody to
determine the extent of co-localization of LBH2 with this important VMH molecule. In
rostral VMH sections, SF-1 appeared to be localized to every division of the VMH
(dmVMH, intVMH, and vlVMH), whereas LBH2 was only present in the dmVMH and
intVMH (Fig. 29). The LBH2 neuronal population appears to be a subset of the SF-1
population, as no LBH2 neurons were observed that did not express SF-1. In caudal
VMH sections, neither LBH2 nor SF-1 appeared to be expressed in the vlVMH, the
location of the estrogen receptor-alpha neuronal population (Simerly et al., 1990).
Instead, both proteins were predominantly located in the intVMH. Again, no LBH2
neurons were observed that did not also express SF-1. In general, it appears that LBH2 is
expressed in roughly 70 percent of SF-1 neurons in the VMH.
Because of the lack of prominence of LBH2 staining in the vlVMH, we
investigated to what extent LBH2 expression overlapped to any extent with that of
estrogen receptor-alpha. ERalpha is expressed widely throughout the hypothalamus, but
within the VMH is expressed at low levels in the dmVMH and at extremely high levels in
the vlVMH (Simerly et al., 1990). Estrogen receptor neurons in the vlVMH are
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Figure 28 Co-visualization of LBH2-eGFP and NeuN in the VMH
Dual-fluorescence confocal images of LBH2-eGFP brain sections
stained with both anti-NeuN (red) and anti-GFP (green). (a) 40x images
of dmVMH. (b) Merged larger composite image containing the entire
VMH.
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Figure 29 Co-Visualization of LBH2-eGFP and SF-1 in the VMH
Double-label immunohistochemistry with mouse anti-GFP and rabbit anti-SF-1
antibodies performed on rostral (left) and caudal (right) hypothalamic sections from
LBH2-eGFP BAC transgenic mice. Scale bars, 200 µm.

implicated in a number of physiological functions, but most particularly in the initiation
of the female sexual response lordosis (Etgen, 1987). We examined ER-alpha expression
in LBH2-GFP mice by double label immunohistochemistry. In the dmVMH, where ERalpha is expressed at low levels, there was significant overlap with LBH2. However, in
the vlVMH, where ER-alpha expression is most prominent, no overlap between LBH2GFP and ERalpha expression was observed, even though LBH2 is expressed in a small
number of vlVMH neurons (Fig. 30).
Because LBH2 is prominently expressed in the dmVMH, we next asked to what
extent LBH2 expression was associated with leptin responsiveness. Because there are no
antibodies available that can be used to visualize leptin receptor neurons by
immunohistochemistry, the best available means of identifying leptin responsive neurons
is to treat animals with leptin and perform immunohistochemistry with an antibody
specific for activated, phosphorylated STAT3, visualized in the nucleus by horseradish
peroxidase-diaminobenzidine (DAB) staining. Animals were fasted for 24 hours prior to
leptin treatment in order to reduce endogenous leptin levels, and then treated with 1mg/kg
leptin IP. After waiting for 45 minutes for optimal activation of STAT3, the animals
were perfused and processed for immunohistochemistry. Animals treated with leptin
displayed abundant pSTAT3 immunoreactivity, within the VMH restricted primarily to
the dmVMH. When this staining was performed on LBH2-GFP animals, in conjunction
with fluorescent anti-GFP immunohistochemistry, significant overlap was observed
between LBH2 expression and pSTAT3 signal. The pStat3 DAB staining diminished the
GFP fluorescence of LBH2-GFP neurons in the perinuclear area, revealing dual-positive
neurons by a characteristic halo (Fig. 31). However, this phenomemon is difficult to
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Figure 30 Co-Visualized VMH Distributions of LBH2 and Estrogen Receptor-alpha
(a-c) Dual-color fluorescence images of dmVMH stained with anti-estrogen receptoralpha (red) and anti-GFP (green). Magnification, 20x; scale bars, 100 µm. (d-f)
Dual-color fluorescence images of dmVMH stained with anti-estrogen receptor-alpha
(red) and anti-GFP (green). Magnification, 10x; scale bars, 50 µm.
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Figure 31 Leptin Responsiveness of VMH LBH2 Neurons
Simultaneous visualization of pStat3 and GFP in the VMH of LBH2-eGFP BAC transgenic
mice. pStat3 (a, c) is visualized following 24 hour fast and 45 min treatment with 1 mg/kg
leptin IP by anti-pStat3 antibody and ABC-DAB staining. GFP (b, d) is visualized by antiGFP immunofluorescence. Green halos represent double-stained neurons. (a-b) Brightfield
and fluorescence images of dmVMH at 20x. Scale bars, 100 µm. (c-d) Brightfield and
fluorescence images of dmVMH at 40x. Scale bars, 50 µm.

quantitate, thus it was difficult to determine whether all pSTAT3 containing neurons
were LBH2 positive, but at least 90% of leptin responsive neurons were found to be in
the LBH2-expressing population.

Tracing VMH -> ARC Projections Using Pseudorabies Virus
It has been a source of debate in recent years how the VMH is integrated into the
neuronal circuit regulating feeding and body weight. Staining of VMH neurons reveals
an axonal field that extends around the area of the nucleus, reaching the VMH/ARC and
VMH/DMH boundaries, but not progressing further (Saper et al., 1976a). The initial
assumption was that VMH neurons did not synapse with ARC or DMH neurons.
However, analysis of ARC neurons showed that the ARC was heavily populated by
neurons that extended dendrites to this same internuclear zone. Recently, Sternson et al.,
using

a

laser-scanning

photostimulation

(LSPS)

technique

incorporating

electrophysiology and focal release of caged glutamate, identified extensive connections
between the VMH and the ARC (Sternson et al., 2005). Specifically, it was determined
that POMC neurons in the ARC received inputs from medial VMH neurons, while
NPY/AgRP neurons in the ARC received inputs from the intVMH and vlVMH. Though
this approach revealed a beautiful array of connectivity between these two nuclei, the
technique precludes the possibility of identifying specific neurons in the VMH that
project to the ARC. To this end, we attempted to reproduce some of the LSPS findings
using a different tracing system, pseudorabies virus.
Pseudorabies virus (PRV) represents an extremely powerful tool for tracing
neuronal pathways (Strack et al., 1989a). PRV infects in a step-wise manner from neuron
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to neuron via synaptic connections, in a retrograde- or bi-directional direction, depending
on the strain. PRV has been used extensively to map connections in the CNS and outputs
to various peripheral organs. However, the use of PRV was traditionally limited by the
inability to initiated infection in specific cells, thus observing the inputs to particular
defined sets of neurons. This problem was overcome by the development of a credependent virus strain, Ba2001, which requires cre for expression of the essential viral
gene thymidine kinase (TK) and a marker, GFP (DeFalco et al., 2001). Using this virus,
DeFalco et al. traced the inputs of leptin receptor neurons in the arcuate nucleus using an
Ob-Rb cre mouse line.
To trace VMH projections to the ARC, we utilized AgRP-cre mice (kind gift of
Dr. Bob McKenzie, Wayne State University, Detroit, MI). Because AgRP is expressed
exclusively in the ARC within the entire mouse brain, we were able to use a TK+ variant
of Ba2001. This virus is infectious and kills both wild-type and cre animals, but it is
totally conditional for GFP expression. Using the TK+ variant eliminated the necessity
of total accuracy of stereotaxic injection into the ARC. An infection into a nearby area
will spread to the ARC, where GFP expression will become activated by the cre
recombinase, and subsequently any neurons infected by the virus from those cre neurons
will also express GFP.
Ba2001TK+ was stereotaxicly injected into the ARC of both wild-type and
AgRP-cre mice. In AgRP-cre mice infected with Ba2001TK+, strong GFP fluorescence
was observed in the ARC, VMH, PVN, amygdala, lateral septal nucleus, superoptic
nucleus, and nucleus of the solitary tract (Fig. 32 a-f). In contrast, no GFP was observed
anywhere in the brains of wild-type control animals injected with the Ba2001TK+ virus
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Figure 32 Ba2001TK+ Infection of AgRP-Cre
and WT Mice
Immunohistochemistry for GFP 3 days following
stereotaxic injection of Ba2001TK+ into the ARC
of AgRP-cre (left) or WT control mice (right). In
AgRP-cre mice, GFP is visible in the ARC and
VMH (a), PVN (b), solitary nucleus (c), superoptic
nucleus (d), lateral septal nucleus (e), and amygdala
(F). In contrast, no GFP is observed in WT control
mice infected with the same virus. Shown is the
mediobasal hypothalamus (g, h) and PVN (i).
Scale bars, 200 µm.

(Fig. 32 g-i). In the VMH, GFP was observed most prominently in the intVMH, with
appreciable staining in the dmVMH. Less signal was observed in the vlVMH.
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Chapter 4: Discussion

VMH Marker Genes
The use of marker genes to dissect complex neural circuits has previously been
applied in studies of several brain regions revealing important and in some cases
divergent responses of specific neurons in specific brain regions (Elias et al., 1999; Pinto
et al., 2004). While several lines of evidence have established that the VMH plays an
important role in controlling food intake, glucose metabolism and body weight (Elmquist
et al., 1999), efforts to determine how specific classes of VMH neurons mediate these
processes have been hampered by the lack of a set of marker genes that could facilitate a
molecular analysis of their function. The importance of understanding the functional
roles of specific neurons in this nucleus is further amplified by the observation that
VMH-specific knockout of the leptin receptor leads to increased adiposity and body
weight (H. Dhillon, personal communication). In these studies it was not known which
VMH neurons are responsible for this effect.
We have successfully used LCM coupled with cDNA microarrays to generate an
initial set of VMH enriched genes. In the future, this set may be expanded using a similar
approach in combination with microarrays composed of different clones from those used
here. Of the twelve top VMH candidates predicted to be VMH-enriched from the
microarray results, nine were successfully validated by real-time PCR analysis of RNA
from freshly microdissected ARC, VMH, and DMH tissue. These genes include SF-1,
PACAP, Cbln1, LBH2, Slit3, guanine deaminase, TenM2, 3-OST-4, and EST AA982708.
None of these genes were regulated in the hypothalamus in response to fasting.
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It is noteworthy that the expression levels of most genes on the arrays were quite
similar among the three nuclei analyzed. This was to be expected, as the tissues being
compared are physically quite similar to each other. In terms of general expression
patterns in hypothalamic nuclei, it was observed that, whereas the ARC and VMH
appeared to have a significant number of uniquely expressed genes, this was less true for
the DMH. It is possible that gene expression in the DMH is more promiscuous, and that
the DMH may lack its own unique transcriptional network.
In situ hybridization was used to examine the subnuclear expression patterns of
three of the nine VMH enriched genes (Cbln1, PACAP, and a novel gene we have named
LBH2), as well as to further validate the results of the real-time PCR. These genes were
chosen based on their robust VMH expression as well as their potential functional role(s).
PACAP encodes a neuropeptide that has previously been strongly implicated in metabolic
function. PACAP peptide, when administered to mice via the third ventricle, leads to a
sharp reduction of food intake (Mizuno et al., 1998b). Additionally, PACAP knockout
mice exhibit severe metabolic disorders, including impairments to thermogenesis and the
counter-regulatory response to hypoglycemia (Gray et al., 2001; Gray et al., 2002). The
VMH has been shown to play a role in both of these processes, suggesting that PACAP
may contribute to some portion of these VMH functions (Perkins et al., 1981; Borg et al.,
1997). Cerebellin 1 was originally identified as a 16 aa peptide, isolated from rat
cerebellum (Slemmon et al., 1984). The precursor protein from which this 16 aa peptide
is derived displays some similarity to circulating complement C1q, suggesting that this
precursor protein may be the authentic ligand for cerebellin signaling (Urade et al., 1991).
While Cbln1 has been shown by radioimmunoassay to be expressed in the hypothalamus,
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its distribution within this region has not been examined (Satoh et al., 1997). Here we
show that the main site of Cbln1 expression in the hypothalamus is indeed the VMH.
Cerebellin is believed to exert a neuromodulatory activity, and has been shown to
increase the steroidogenic capacity of the adrenal gland. It is possible that, because of
this profile of activity, it may operate either in the same pathway or a parallel pathway to
SF-1 (Albertin et al., 2000; Hochol et al., 2001). LBH2 is a novel gene which shares
significant homology with LBH, a presumed transcription factor postulated to play a role
in limb and heart development (Briegel and Joyner, 2001). Sequence alignment shows
this new gene to be evolutionarily conserved among a number of species. The mRNA for
this gene is short, ~800 bp, and the vast majority of its expression in the body is confined
to the VMH. The function of this VMH enriched transcript awaits further studies,
currently underway.
The expression patterns of the three genes tested showed some variation in the
pattern of subnuclear expression within the VMH.

While PACAP and Cbln1 were

observed to be strongly expressed in all major compartments of the VMH, including the
dmVMH, intVMH and vlVMH, LBH2 expression was almost completely absent in the
vlVMH. Similarly, in the most caudal sections of the VMH, while PACAP and Cbln1
were observed most strongly in the vlVMH, LBH2 was mostly restricted to the intVMH
This proves a signficant variability in gene expression within the VMH. On a larger
scale, the near-total restriction of the tested RNAs to the VMH within the hypothalamus
validates the approach and suggests that the other genes enriched in the VMH using
microarray analysis followed by real-time PCR are likely also legitimate VMH markers.
These genes include Slit3, 3-OST-4 , TenM2, Guanine Deaminase, and EST AA982708.
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Among these genes, 3-OST-4 belongs to a family of sulfotransferases which chemically
modify heparan sulfate proteoglycans (HSPGs) (Shworak et al., 1999). These are large
cell-surface complexes that bind extracellular ligands and are believed to play a role in,
among other things, the modulation of intercellular signaling (Bernfield et al., 1999).
Transgenic mice expressing another HSPG, syndecan-1, in multiple tissues including the
hypothalamus, display obesity secondary to impairment of alpha-MSH signaling in the
hypothalamus (Reizes et al., 2001; Reizes et al., 2003). HSPGs and their modifying
enzymes are often tightly regulated to respond to stimuli, suggesting that 3-OST-4 may
play a role in signal modification in the VMH. Little is known about EST AA982708
(located on mouse chromosome 2) but the fact that the level of its RNA is reduced in
hypothalamus from SF-1 knockout mice suggests that it too may merit further study.
Like LBH2, this transcript was present only on the subtracted hypothalamic cDNA array
and not on the 28,000 gene array which was largely composed of embryonic and adult
mouse cDNA clones. Thus it appears that, as was the case for LBH2, the hypothalamus
(and by extension the VMH) is the primary site of expression of this EST in the mouse.

Steroidogenic Factor 1
Several of the VMH enriched genes were dysregulated in SF-1 knockout mice.
SF-1 is an orphan nuclear receptor that plays a critical role in the embryonic development
of the VMH (Ikeda et al., 1995). Proper differentiation and migration of VMH neurons
during development is presumed to be associated with the activation of a number of SF-1
target genes. While direct targets of SF-1 have been identified in the adrenal gland
including cholesterol side chain cleavage enzyme, steroid 21-hydroxylase and the

112

aldosterone synthase isozyme of steroid 11 beta-hydroxylase, few of its VMH targets
have been identified (Parker and Schimmer, 1997). Four out of eight VMH markers
tested (Cbln1, Slit3, TenM2, and EST AA982708) were significantly downregulated in
mutant neurons.
The proper formation of the VMH during development clearly relies on a
downstream SF-1 regulated gene. Without SF-1, the VMH neurons are diffusely spread
throughout the hypothalamus. It is difficult to imagine a mechanism for co-migration and
coalescence of a specific group of neurons without invoking the existence of a specific
signaling molecule or molecules (either a secreted factor, receptor, or intracellular
signaling molecule, or any combination of the above) expressed only by those specific
neurons. Such a factor would necessarily be expressed by VMH neurons, but not by their
non-VMH neighbors, and must also be regulated by SF-1. By this reasoning, those genes
that comprise the subset of VMH markers that are regulated by SF-1 all represent strong
candidates for involvement in the development of the VMH and the resulting phenotype
of the SF-1 knockout mouse.
Among these genes, Slit3 especially stood out, as the Slit genes, along with their
Robo receptors, are known regulators of cell migration and axon guidance (Wu et al.,
1999). However, examination of the VMH neuron distribution in Slit3 knockout mice
revealed no obvious abnormalities. The VMH appeared grossly normal by staining with
an anti-NeuN antibody, and the estrogen receptor-alpha neuron population was of normal
appearance. Because the Slit genes are implicated in both neuronal migration and axon
guidance, it remains possible that the VMH neurons of Slit3 knockout mice have an axon
guidance phenotype. However, it was not possible to observe the neuronal connectivity
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in the fixed brain tissue available. In the future, to examine the connectivity of these
neurons in Slit3 knockout mice, VMH projections could be examined using the axonal
tracer DiI in analagous studies to those used on the ARC (Bouret et al., 2004a, b).
Alternatively, Slit3 -/- mice could be crossed to AgRP-cre or POMC-cre mice in order to
test the VMH -> ARC connections using a conditional PRV strain. Even in the event that
Slit3 plays no role in the organization of the VMH, it is likely that some or all these genes
are direct or indirect targets of SF-1. As such, there is a chance that each of them may
play some kind of role in VMH development. All of these genes merit further study.

LBH2-GFP Mice: Markers as Tools to Understand the VMH
The marker genes reported here thus constitute a set of reagents that can be used
to attempt to define distinct cell types in the VMH. Knowledge about specific cell types
would make possible future efforts to study their function. The definition of neuronal
subtypes based on the expression of marker gene expression rather than anatomic
localization or morphology offers a number of experimental advantages. For example, it
has been shown that the POMC and NPY neurons in the ARC, which are not
distinguishable on the basis of localization or morphology, display opposing responses to
treatment with leptin, both with regard to activity and plasticity (Elias et al., 1999; Pinto
et al., 2004).

Defining neuronal subpopulations on the basis of gene expression is

additionally advantageous because it allows for the introduction of a marker or other
genes specifically to those neurons using BAC-mediated transgenesis. Bacterial artificial
chromosomes (BACs) can be easily modified to express a transgene usually under the
control of the full set of regulatory elements necessary for the eutopic expression of that
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gene (Gong et al., 2002). BAC transgenic mice expressing GFP in specific classes of
neurons have proven extremely useful for electrophysiological studies, electron
microscopy-based assays of neuronal plasticity and synaptogenesis, cell culture assays,
and gene expression studies of nuclear subpopulations (Pinto et al., 2004; Roseberry et
al., 2004).
To this end, we produced BAC transgenic mice expressing eGFP under the
control of the LBH2 promoter (LBH2-eGFP).

These mice display bright green

fluorescence in all of the sites of expression of LBH2 as determined by in situ
hybridization. They do exhibit spurious expression in the piriform cortex. In the VMH,
all eGFP-expressing neurons do in fact express LBH2, though there appear to be a small
number of unlabeled LBH2 neurons. LBH2 appears to be expressed in roughly 80% of
dmVMH neurons, and a lesser number (roughly 60%) of intVMH neurons. LBH2 is only
expressed rarely in the vlVMH, where it shows a nearly complete non-overlapping
profile with estrogen receptor-alpha.

A comparison of LBH2 expression and SF-1

expression shows that, as expected, they show substantial overlap in the dmVMH and
intVMH. In rostral VMH sections, SF-1 is significantly expressed in the vlVMH, while
LBH2 is not. However, in the caudal vlVMH, neither SF-1 nor LBH2 appear to be
expressed (it is possible that SF-1 is expressed here at low levels), and they show
significant overlap in the intVMH. In all sections, LBH2 neurons represent only a subset
of SF-1 neurons (with similar numbers as described above), as SF-1 appears to be
expressed in all VMH neurons in the regions where it is present. The fact that LBH2
shows a more medial expression pattern than SF-1, PACAP, and Cbln1 suggests that it
may serve as a useful driver for transgenes targeted to only the dmVMH and vlVMH. As
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discussed, these regions are primarily implicated in the response to leptin and the
regulation of food intake and body weight, while the vlVMH is most implicated in sexual
behavior. Thus, LBH2 might represent a powerful tool to dissect the differences between
these segments of the VMH.
Clearly, there are many avenues for further research on the VMH made possible
as a result of these results. Other BAC transgenic mice expressing fluorescent proteins
under the control of other VMH markers would be extremely useful for the
combinatowrial studies necessary to fully define VMH neuronal subsets on the basis of
gene expression. There are limitless options available for use of the marker genes to
express of a wide array of transgenes. GFP mice, in addition to neuroanatomical studies,
would be extremely useful for electrophysiological studies and studies of neuronal
plasticity. Mice expressing cre recombinase in particular subsets would allow for tracing
experiments using a variety of retrograde and anterograde transneuronal tracers. Perhaps
most intriguing, expression of transgenes designed to modulate neuronal function and
activity. The ability to exert spatiotemporal control over the activation or inhibition of
specific neuronal populations would allow direct observations of their impact on the
output of a circuit, whether it be behavioral or metabolic.

Conditional Pseudorabies Virus Tracing
Pseudorabies virus has been used extensively to trace neuronal circuitry, owing to
its advantageous characteristic of infecting in a retrograde manner via synaptic
connections. However, the advent of conditional strains of PRV that are conditional
upon cre recombinase expression for viability and/or GFP expression have brought this
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technology to a new level, allowing detailed transneuronal tracing from discrete
populations of neurons (DeFalco et al., 2001).
Here, we have used a viable, TK+ strain of Ba2001 that is conditional for GFP
expression only. The absolute restriction of the cre enzyme to one region of interest in the
brain is a specific requirement for the use of this virus for tracing initiated in the CNS. If
the cre enzyme were expressed in other areas, the virus would be able to spread there and
then become GFP-positive at multiple sites. In such a case, it would be impossible to
determine the origin of GFP-positive staining at a distal second-order site.
In wild-type control animals, minimal to no GFP expression is observed following
infection with Ba2001TK+. In AgRP-cre animals, bright fluorescence was observed in
the ARC and several upstream sites, including the VMH. This represents significant
corroborating evidence for the finding that the VMH sends significant projections to the
ARC.

More excitingly, because this system allows for definitive identification of

individual neurons that send outputs to cre-expressing neurons, this system can be used in
conjunction with the set of VMH markers identified here to determine the identity of
VMH neurons that project to ARC AgRP neurons.

Using traditional Ba2001 in

conjunction with POMC-cre mice would, in an analagous fashion, be useful for learning
about VMH subpopulations that project to these important anorexigenic neurons.
Knowledge about the particular VMH neuronal subtypes that project to ARC neurons
would be extremely valuable. While it is clear that the VMH is profoundly important for
energy homeostasis and for responding to leptin, it is wholly unclear how the VMH
accomplishes these tasks. Detailed information about VMH neuronal wiring would allow
for future experiments designed to understand the importance of particular VMH outputs
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to other nuclei. For example, if subsets of VMH neurons that project to ARC neurons
could be identified, these populations could be modulated to begin to understand whether
VMH outputs to the ARC are the essential mediators of leptin’s action on the VMH.
Studies such as these will be essential steps along the path to a full description of
hypothalamic feeding pathways that respond to leptin and other central and peripheral
signals.
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Conclusion

The ventromedial hypothalamic nucleus plays a central role in energy homeostasis, but
study of this nucleus has been hampered by a lack of available marker genes to label its
constituent neurons.

We have used LCM in conjunction with cDNA microarray

technology to develop a set of markers, and have begun to use those markers to learn
about the component populations that make up this important nucleus. Additional studies
of SF-1 knockout mice addressed the regulation of these genes, suggesting that LCM
coupled with microarray analysis may be effective for uncovering nucleus-specific
transcriptional networks. The techniques used in this thesis are not restricted to study of
the VMH. They may be just as easily applied to other nuclei and subnuclei, whether they
be in the hypothalamus or other regions of the brain. Marker identification, followed by
definition of nuclear subtypes and subsequent transgenic approaches to study those
subtypes, represents a generally applicable strategy to dissecting the composition,
connectivity and function of any poorly characterized brain region.
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